{"content":"<li class=\"n-box-item date-title\" data-end=\"1516769999\" data-start=\"1516683600\" data-txt=\"Monday, December 23, 2019\">Tuesday, January 23, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3324718\" data-ts=\"1516758536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324718-united-continentalminus-6-on-plans-to-match-low-fares-expand-capacity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Continental -6% on plans to match low fares, expand capacity</a></h4><ul>     <li>United Continental (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>) <font color='red'>-6.4%</font> after-hours, sharply reversing initial gains following better than expected <a href=\"https://seekingalpha.com/news/3324652-ual-rides-higher-earnings\" target=\"_blank\">Q4 earnings</a>.</li>     <li><a href=\"https://www.reuters.com/article/us-ual-results/united-air-shares-tumble-as-it-vows-to-match-low-fares-expand-capacity-idUSKBN1FC30R?il=0\" target=\"_blank\">Investors were spooked</a> by comments in UAL's earnings conference call that the company plans to increase capacity, as an exec said &ldquo;The best way to compete with low-cost carriers is to match their prices. We can&rsquo;t let low-cost carriers have price advantages in our hubs.&rdquo;</li>     <li>UAL said it expects to increase its capacity by 4%-6% in 2018 and probably by a similar amount in 2019 and 2020.</li><li>Also lower after-hours: <a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='red'>-4.7%</font>, <a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='red'>-4.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324718\" data-linked=\"United Continental -6% on plans to match low fares, expand capacity\" data-tweet=\"$UAL $UAL $DAL - United Continental -6% on plans to match low fares, expand capacity https://seekingalpha.com/news/3324718-united-continentalminus-6-on-plans-to-match-low-fares-expand-capacity?source=tweet\" data-url=\"https://seekingalpha.com/news/3324718-united-continentalminus-6-on-plans-to-match-low-fares-expand-capacity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324712\" data-ts=\"1516751968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDS\" target=\"_blank\">GDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324712-gdsminus-4_9-on-news-of-8m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GDS -4.9% on news of 8M-share offering</a></h4><ul>   <li>GDS Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a>) has <font color='red'>fallen 4.9%</font> after hours after word it will <a href=\"https://seekingalpha.com/pr/17054419-gds-announces-launch-proposed-public-offering-adss\" target=\"_blank\">sell 8M</a> of its American Depositary Shares in a public offering.</li>    <li>Entities associated with one of its major shareholders, SBCVC Holdings, are selling 1.5M ADS in the offering as well.</li>    <li>Each ADS represents eight of its class A ordinary shares.</li>    <li>Underwriters will have a 30-day option to buy up to an additional 1.425M ADS at the offering price.</li>    <li>Net proceeds will go to acquiring new data centers and for general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324712\" data-linked=\"GDS -4.9% on news of 8M-share offering\" data-tweet=\"$GDS - GDS -4.9% on news of 8M-share offering https://seekingalpha.com/news/3324712-gdsminus-4_9-on-news-of-8m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324712-gdsminus-4_9-on-news-of-8m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324709\" data-ts=\"1516749003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNI\" target=\"_blank\">CNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324709-canadian-national-railminus-2-after-q4-earnings-miss-downside-2018-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian National Rail -2% after Q4 earnings miss, downside 2018 guidance</a></h4><ul>     <li>Canadian National Railway (NYSE:<a href='https://seekingalpha.com/symbol/CNI' title='Canadian National Railway Company'>CNI</a>) <font color='red'>-2.2%</font> after-hours as it reports mixed <a href=\"https://seekingalpha.com/news/3324616-canadian-national-railway-misses-c-0_03-beats-revenue\" target=\"_blank\">Q4 results</a>, missing expectations on earnings but beating on revenues, while <a href=\"https://seekingalpha.com/news/3324630-canadian-national-railway-declares-cad-0_455-dividend\" target=\"_blank\">raising its quarterly dividend by 10%</a>.</li>     <li>CNI's Q4 operating cost to revenue ratio was higher than in the year-ago quarter, indicating slightly lower company efficiency.</li>     <li>CNI also issues below-consensus guidance for FY 2018 earnings, now seeing EPS of C$5.25-C$5.40, vs. C$5.51 analyst consensus estimate.</li>     <li>Separately, CNI unveils a C$3.2B capital spending program for 2018, including C$700M to increase capacity - including the acquisition of 60 new locomotives, track infrastructure expansion and improvements at intermodal terminals - and C$1.6B for track infrastructure maintenance  supporting safety and efficiency.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324709\" data-linked=\"Canadian National Rail -2% after Q4 earnings miss, downside 2018 guidance\" data-tweet=\"$CNI - Canadian National Rail -2% after Q4 earnings miss, downside 2018 guidance https://seekingalpha.com/news/3324709-canadian-national-railminus-2-after-q4-earnings-miss-downside-2018-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3324709-canadian-national-railminus-2-after-q4-earnings-miss-downside-2018-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324695\" data-ts=\"1516747311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVRS\" target=\"_blank\">CVRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324695-corindus-reports-strong-preliminary-q4-fy17-results-sharesplus-25-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corindus reports strong preliminary Q4 &amp; FY17 results; shares +25% AH</a></h4><ul>     <li>Corindus Vascular Robotics (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVRS' title='Corindus Vascular Robotics, Inc.'>CVRS</a>) expects Q4 revenue in the range of $4.0M - $4.2M vs. a consensus of $3.45M.</li>     <li>The company expects FY17 revenue in the range of $9.5M - $9.7M&nbsp; vs. a consensus of $8.9M.</li>     <li>\"Our fourth quarter accomplishments reflect continued progress toward our strategic objectives,\" said Mark Toland. \"Our results are highlighted by meaningful strategic partnerships with leading institutions which validates our GRX robotic technology platform and the benefits it provides to hospitals and their patients.\"</li><li>Shares&nbsp;<font color='green'>+25% AH</font></li><li><a href=\"https://seekingalpha.com/pr/17054403-corindus-announces-preliminary-fourth-quarter-full-year-2017-revenue\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3324695\" data-linked=\"Corindus reports strong preliminary Q4 &amp; FY17 results; shares +25% AH\" data-tweet=\"$CVRS - Corindus reports strong preliminary Q4 &amp; FY17 results; shares +25% AH https://seekingalpha.com/news/3324695-corindus-reports-strong-preliminary-q4-fy17-results-sharesplus-25-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3324695-corindus-reports-strong-preliminary-q4-fy17-results-sharesplus-25-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324693\" data-ts=\"1516746806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324693-after-hours-gainers-losers-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (1/23/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a> <font color='green'>+20.1%</font>. <a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a> <font color='green'>+7.7%</font>. <a href='https://seekingalpha.com/symbol/CASC' title='Cascadian Therapeutics, Inc'>CASC</a> <font color='green'>+2.5%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/TVIX' title='VelocityShares Daily 2x VIX Short-Term ETN'>TVIX</a> <font color='green'>+2.0%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-27.9%</font>. <a href='https://seekingalpha.com/symbol/SIGM' title='Sigma Designs, Inc.'>SIGM</a> <font color='red'>-11.4%</font>. <a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a> <font color='red'>-7.8%</font>. <a href='https://seekingalpha.com/symbol/TK' title='Teekay Corporation'>TK</a> <font color='red'>-7.3%</font>. <a href='https://seekingalpha.com/symbol/TXN' title='Texas Instruments Inc.'>TXN</a> <font color='red'>-6.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324693\" data-linked=\"After Hours Gainers / Losers (1/23/2018)\" data-tweet=\"$CERS $ARAY $CASC - After Hours Gainers / Losers (1/23/2018) https://seekingalpha.com/news/3324693-after-hours-gainers-losers-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324693-after-hours-gainers-losers-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324680\" data-ts=\"1516744788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIGM\" target=\"_blank\">SIGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324680-sigma-designsminus-8_6-on-unit-sale-after-acquisition-falls-through\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sigma Designs -8.6% on unit sale after acquisition falls through</a></h4><ul><li>        Sigma Designs (NASDAQ:<a href='https://seekingalpha.com/symbol/SIGM' title='Sigma Designs, Inc.'>SIGM</a>) <a href=\"https://seekingalpha.com/pr/17054314-sigma-designs-inc-announces-plan-sell-z-wave-business-240-million\" target=\"_blank\">announces</a> plans to sell its Z-Wave business to Silicon Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SLAB' title='Silicon Laboratories, Inc.'>SLAB</a>) for $240M in cash.</li><li>               Silicon Labs had planned to acquire all of Sigma Designs but the initial closing conditions weren&rsquo;t satisfied.&nbsp;</li><li>               Sigma expects the transaction to close in late Q1 or early Q2 of CY18. &nbsp;&nbsp;</li><li>               After the close, Sigma will initiate a liquidation plan that will include a substantial cash distribution to shareholders.&nbsp;</li><li>                  Sigma Designs shares are&nbsp;<font color='red'>down 8.6%</font>&nbsp;aftermarket.    &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3324680\" data-linked=\"Sigma Designs -8.6% on unit sale after acquisition falls through\" data-tweet=\"$SIGM $SIGM $SLAB - Sigma Designs -8.6% on unit sale after acquisition falls through https://seekingalpha.com/news/3324680-sigma-designsminus-8_6-on-unit-sale-after-acquisition-falls-through?source=tweet\" data-url=\"https://seekingalpha.com/news/3324680-sigma-designsminus-8_6-on-unit-sale-after-acquisition-falls-through\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324676\" data-ts=\"1516744366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARAY\" target=\"_blank\">ARAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324676-fq2-beat-propels-accuray-up-9-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FQ2 beat propels Accuray, up 9% after hours</a></h4><ul><li>Accuray (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a>) <a href=\"https://seekingalpha.com/pr/17054232-accuray-fiscal-second-quarter-revenue-exceeds-100-million-increases-15-percent-year-year\" target=\"_blank\">fiscal Q2 results</a> ($M): Net revenue: 100.3 (+14.6%).</li><li>Net Loss: (4.7) (+50.0%); Loss/share: (0.06) (+45.5%); non-GAAP EBITDA: 4.8 (+168.9%).</li><li>10% increase in backlog.</li><li>Consensus view: Loss/share of ($0.10) on revenue of 90.3M.</li><li><strong>Fiscal 2018 guidance</strong>: Revenue: $390M - 400M; non-GAAP EBITDA: $25M - 30M.</li><li>Shares are up&nbsp;<font color='green'>9%&nbsp;</font>after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324676\" data-linked=\"FQ2 beat propels Accuray, up 9% after hours\" data-tweet=\"$ARAY - FQ2 beat propels Accuray, up 9% after hours https://seekingalpha.com/news/3324676-fq2-beat-propels-accuray-up-9-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3324676-fq2-beat-propels-accuray-up-9-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324673\" data-ts=\"1516743937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXN\" target=\"_blank\">TXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324673-texas-instrumentsminus-5_4-after-q4-results-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas Instruments -5.4% after Q4 results, in-line guidance</a></h4><ul><li>        Texas Instruments (NYSE:<a href='https://seekingalpha.com/symbol/TXN' title='Texas Instruments Inc.'>TXN</a>) shares are&nbsp;<font color='red'>down 5.4%</font>&nbsp;aftermarket following Q4 results that beat on revenue and met on EPS. In-line Q1 guidance has revenue from $3.49B to $3.79B (consensus: $3.63B) and EPS from $0.98 to $1.14 (consensus: $1.04).</li><li>               Segment results: Analog, $2.5M (+11% Y/Y); Embedded Processing, $896M (+20%); Other, $319M (-16%).&nbsp;</li><li>               Key metrics: cash flow from operations, $1.9B; capital expenditures, $231M; FCF, $1.7B; cash and equivalents, $1.7B; total liabilities, $7.3M.&nbsp;</li><li>               Tax reform impact: Annual operating tax rate will drop from 31% last year to an ongoing rate of 18% starting in 2019. For 2018, operating tax rate will be 23%.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17054227-ti-reports-4q17-2017-financial-results-shareholder-returns\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324612-texas-instruments-eps-line-beats-revenue\" target=\"_blank\">Texas Instruments EPS in-line, beats on revenue</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324673\" data-linked=\"Texas Instruments -5.4% after Q4 results, in-line guidance\" data-tweet=\"$TXN - Texas Instruments -5.4% after Q4 results, in-line guidance https://seekingalpha.com/news/3324673-texas-instrumentsminus-5_4-after-q4-results-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3324673-texas-instrumentsminus-5_4-after-q4-results-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324671\" data-ts=\"1516743815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERS\" target=\"_blank\">CERS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324671-intercept-treated-rbcs-successful-in-late-stage-thalassemia-study-cerus-up-26-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept-treated RBCs successful in late-stage thalassemia study; Cerus up 26% after hours</a></h4><ul><li>Cerus (NASDAQ:<a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a>) is up&nbsp;<font color='green'>26%</font>&nbsp;after hours on robust volume on the heels of its <a href=\"https://seekingalpha.com/pr/17054305-cerus-reports-positive-top-line-results-chronic-anemia-phase-3-study-evaluating-intercept-red\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, SPARC, assessing the safety and efficacy of transfused INTERCEPT-treated red blood cells (RBCs) in thalassemia patients.</li><li>The results demonstrated non-inferiority between INTERCEPT-treated RBCs and conventional RBCs.</li><li>Complete results will be submitted for presentation at upcoming scientific conferences and for publication.</li><li>An application for CE Mark certification should be filed in H2.</li><li>Management will host a conference call tomorrow, January 24, at 8;30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324671\" data-linked=\"Intercept-treated RBCs successful in late-stage thalassemia study; Cerus up 26% after hours\" data-tweet=\"$CERS - Intercept-treated RBCs successful in late-stage thalassemia study; Cerus up 26% after hours https://seekingalpha.com/news/3324671-intercept-treated-rbcs-successful-in-late-stage-thalassemia-study-cerus-up-26-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3324671-intercept-treated-rbcs-successful-in-late-stage-thalassemia-study-cerus-up-26-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324666\" data-ts=\"1516743356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COF\" target=\"_blank\">COF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324666-capital-one-down-almost-2-after-q4-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital One down almost 2% after Q4 miss</a></h4><ul><li>The company reported a sizable Q4 net loss, but this was helped along by a $1.77B or $3.61 charge related to the tax bill. Adjusted EPS of $1.62 still missed estimates by a full $0.26.</li><li>Among the items which knocked down results was a $113M or $0.15 per share writedown related to the taxi medallion portfolio.</li><li>Credit loss provisions rose 5% Y/Y to $1.9B; net charge-offs were $1.8B, and the reserve build was $98M.</li><li>Domestic card average loans up 8% to $101.1B. Auto average loans up 2% to $53.7B.</li><li><a href=\"http://www.capitalone.com\" target=\"_blank\">Conference call at 5 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3324650-capital-one-financial-misses-0_26-misses-revenue\" target=\"_blank\">Capital One Financial misses by $0.26, misses on revenue</a> (Jan. 23)</li><li><a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a>&nbsp;<font color='red'>-1.9%&nbsp;</font>after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3324666\" data-linked=\"Capital One down almost 2% after Q4 miss\" data-tweet=\"$COF - Capital One down almost 2% after Q4 miss https://seekingalpha.com/news/3324666-capital-one-down-almost-2-after-q4-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3324666-capital-one-down-almost-2-after-q4-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324658\" data-ts=\"1516743196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TK\" target=\"_blank\">TK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324658-teekay-to-launch-stock-convertible-bond-offerings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teekay to launch stock, convertible bond offerings</a></h4><ul>     <li>Teekay Corp. (NYSE:<a href='https://seekingalpha.com/symbol/TK' title='Teekay Corporation'>TK</a>) <font color='red'>-7.7%</font> after-hours as it announces a <a href=\"https://seekingalpha.com/pr/17054249-teekay-corporation-announces-proposed-common-stock-offering\" target=\"_blank\">public offering</a> of 10M common shares, with an underwriters option to purchase up to another 1.5M shares, and another offering to <a href=\"https://seekingalpha.com/pr/17054248-teekay-corporation-announces-proposed-convertible-senior-notes-offering\" target=\"_blank\">sell $100M of convertible senior notes</a> due 2023.</li>     <li>TK says it plans to use the proceeds from the offerings for general corporate purposes, which may include repaying part of its outstanding debt and funding working capital.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324658\" data-linked=\"Teekay to launch stock, convertible bond offerings\" data-tweet=\"$TK - Teekay to launch stock, convertible bond offerings https://seekingalpha.com/news/3324658-teekay-to-launch-stock-convertible-bond-offerings?source=tweet\" data-url=\"https://seekingalpha.com/news/3324658-teekay-to-launch-stock-convertible-bond-offerings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>135&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324656\" data-ts=\"1516743044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324656-european-advisory-group-likely-thumbs-down-on-pumas-neratinib-shares-off-24-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group likely thumbs down on Puma&#39;s neratinib; shares off 24% after hours</a></h4><ul><li>Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) slumps&nbsp;<font color='red'>24%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17054307-puma-biotechnology-announces-results-chmp-oral-explanation-neratinib-extended-adjuvant\" target=\"_blank\">announcement </a>of the outcome of today's oral hearing in Europe related to its marketing application seeking approval for neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer.</li><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; communicated a \"negative trend\" vote after the hearing, meaning that a positive vote on the application is unlikely. CHMP will issue its formal decision next month.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3322500-puma-bio-adjust-proposed-labeling-neratinib-meeting-chmp-oncology-advisory-group-shares-2\" target=\"_blank\">Puma Bio to adjust proposed labeling for neratinib after meeting with CHMP oncology advisory group; shares up 2% after hours</a> (Jan. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324656\" data-linked=\"European advisory group likely thumbs down on Puma&#39;s neratinib; shares off 24% after hours\" data-tweet=\"$PBYI - European advisory group likely thumbs down on Puma&#39;s neratinib; shares off 24% after hours https://seekingalpha.com/news/3324656-european-advisory-group-likely-thumbs-down-on-pumas-neratinib-shares-off-24-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3324656-european-advisory-group-likely-thumbs-down-on-pumas-neratinib-shares-off-24-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324652\" data-ts=\"1516742746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324652-ual-rides-higher-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UAL rides higher after earnings</a></h4><ul>     <li>United Continental (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>) moves higher after sliding past estimates with its Q4 report.</li>     <li>Passenger revenue per available seat mile was up 0.2% during the quarter.</li>     <li>With traffic results released monthly, the company's guidance was the highlight of the report.</li>     <li>United expects unit revenue growth of +0-2%, in Q1 off a capacity increase of 3.5% to 4.5%. Full-year guidance will be doled out on the earnings call later.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324621-united-continental-beats-0_06-beats-revenue\" target=\"_blank\">United Continental beats by $0.06, beats on revenue</a> (Jan. 23)</li><li>UAL&nbsp;<font color='green'>+1.32%</font>&nbsp;AH to $79.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324652\" data-linked=\"UAL rides higher after earnings\" data-tweet=\"$UAL - UAL rides higher after earnings https://seekingalpha.com/news/3324652-ual-rides-higher-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3324652-ual-rides-higher-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324649\" data-ts=\"1516742594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIRI\" target=\"_blank\">SIRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324649-sirius-xmplus-1_8-boosts-buybacks-2b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sirius XM +1.8% as it boosts buybacks by $2B</a></h4><ul>   <li>Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>) is <font color='green'>up 1.8%</font> after hours after news that along with its $0.011 quarterly cash dividend, it's approved <a href=\"https://seekingalpha.com/pr/17054319-siriusxm-declares-quarterly-cash-dividend-adds-2-billion-stock-repurchase-program\" target=\"_blank\">boosting its repurchase program</a> by $2B.</li>    <li>That brings total authorization of the program up to $12B since it was started in early 2013.</li>    <li>It reflects the board's \"desire to continue to return value to stockholders and its confidence in the long-term growth prospects of the Company's business,\" and it says it retains sufficient capital for long-term investments in operations as well as strategic opportunities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324649\" data-linked=\"Sirius XM +1.8% as it boosts buybacks by $2B\" data-tweet=\"$SIRI - Sirius XM +1.8% as it boosts buybacks by $2B https://seekingalpha.com/news/3324649-sirius-xmplus-1_8-boosts-buybacks-2b?source=tweet\" data-url=\"https://seekingalpha.com/news/3324649-sirius-xmplus-1_8-boosts-buybacks-2b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324645\" data-ts=\"1516742439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCG\" target=\"_blank\">SCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324645-scanaminus-5-after-south-carolina-governor-says-customers-should-not-pay-for-reactor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCANA -5% after South Carolina governor says customers should not pay for reactor</a></h4><ul>     <li>SCANA (NYSE:<a href='https://seekingalpha.com/symbol/SCG' title='SCANA Corporation'>SCG</a>) sank in the final hour of trading to finish <font color='red'>-5%</font> after South Carolina Gov. McMaster said the company's South Carolina Electric &amp; Gas subsidiary should be <a href=\"https://www.postandcourier.com/business/gov-mcmaster-says-customers-should-stop-paying-for-reactors-after/article_6820ce0c-0062-11e8-9b1b-a34e34ca0269.html\" target=\"_blank\">forced to eat the costs</a> of its abandoned V.C. Summer nuclear  project.</li>     <li>The governor's critical comments after a government report called into question SCG&rsquo;s claims that it would be bankrupted by the bill; the power company says the audit is \"<a href=\"http://www.thestate.com/news/politics-government/article196132119.html\" target=\"_blank\">demonstrably wrong</a>.\"</li><li>The report gives ammunition to South Carolina lawmakers who want to block SCG from continuing to charge its  electric customers ~$37M/month for the abandoned project, and the governor says it gives the legislators all the information needed to cut nuclear-related rates.</li><li>Shares of Dominion Energy (NYSE:<a href='https://seekingalpha.com/symbol/D' title='Dominion Energy, Inc.'>D</a>), which earlier this month agreed to a merger with SCG, were not affected by the news, finishing <font color='green'>+1%</font>.<br><div><br>Read more here: http://www.thestate.com/news/politics-government/article196132119.html#storylink=cpy</div></li> </ul><div class=\"tiny-share-widget\" data-id=\"3324645\" data-linked=\"SCANA -5% after South Carolina governor says customers should not pay for reactor\" data-tweet=\"$SCG $SCG $D - SCANA -5% after South Carolina governor says customers should not pay for reactor https://seekingalpha.com/news/3324645-scanaminus-5-after-south-carolina-governor-says-customers-should-not-pay-for-reactor?source=tweet\" data-url=\"https://seekingalpha.com/news/3324645-scanaminus-5-after-south-carolina-governor-says-customers-should-not-pay-for-reactor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324632\" data-ts=\"1516742055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOLD\" target=\"_blank\">BOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324632-audentes-therapeutics-launches-150m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Audentes Therapeutics launches $150M stock offering</a></h4><ul><li>Audentes Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a>) <a href=\"https://seekingalpha.com/pr/17054228-audentes-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a $150M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;after hours on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324632\" data-linked=\"Audentes Therapeutics launches $150M stock offering\" data-tweet=\"$BOLD - Audentes Therapeutics launches $150M stock offering https://seekingalpha.com/news/3324632-audentes-therapeutics-launches-150m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324632-audentes-therapeutics-launches-150m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324631\" data-ts=\"1516741975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYBX\" target=\"_blank\">SYBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324631-synlogic-initiates-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synlogic initiates equity offering</a></h4><ul><li>Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) <a href=\"https://seekingalpha.com/pr/17054230-synlogic-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324631\" data-linked=\"Synlogic initiates equity offering\" data-tweet=\"$SYBX - Synlogic initiates equity offering https://seekingalpha.com/news/3324631-synlogic-initiates-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324631-synlogic-initiates-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324629\" data-ts=\"1516741912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AERI\" target=\"_blank\">AERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324629-aerie-pharma-launches-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aerie Pharma launches equity offering</a></h4><ul><li>Aerie Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a>) <a href=\"https://seekingalpha.com/pr/17054246-aerie-pharmaceuticals-announces-public-offering-common-stock\" target=\"_blank\">commences </a>a $75M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324629\" data-linked=\"Aerie Pharma launches equity offering\" data-tweet=\"$AERI - Aerie Pharma launches equity offering https://seekingalpha.com/news/3324629-aerie-pharma-launches-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324629-aerie-pharma-launches-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324628\" data-ts=\"1516741909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBSH\" target=\"_blank\">UBSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324628-union-bankshares-backers-selling-shares-down-1_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Bankshares backers selling; shares down 1.2%</a></h4><ul><li>The bank announces a secondary offering of 7.9M shares to be offered by two selling shareholders.</li><li>Union (NASDAQ:<a href='https://seekingalpha.com/symbol/UBSH' title='Union Bankshares Corporation'>UBSH</a>) will receive no proceeds from the sale.</li><li>Shares&nbsp;<font color='red'>-1.2%</font>&nbsp;after hours</li><li>Source: <a href=\"https://seekingalpha.com/pr/17054239-union-bankshares-corporation-announces-secondary-offering\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3324628\" data-linked=\"Union Bankshares backers selling; shares down 1.2%\" data-tweet=\"$UBSH $AUB - Union Bankshares backers selling; shares down 1.2% https://seekingalpha.com/news/3324628-union-bankshares-backers-selling-shares-down-1_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3324628-union-bankshares-backers-selling-shares-down-1_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324623\" data-ts=\"1516741819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324623-rocket-pharmaceuticals-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocket Pharmaceuticals readies stock offering</a></h4><ul><li>Rocket Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a>) <a href=\"https://seekingalpha.com/pr/17054231-rocket-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>7%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324623\" data-linked=\"Rocket Pharmaceuticals readies stock offering\" data-tweet=\"$RCKT - Rocket Pharmaceuticals readies stock offering https://seekingalpha.com/news/3324623-rocket-pharmaceuticals-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324623-rocket-pharmaceuticals-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324622\" data-ts=\"1516741738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FPRX\" target=\"_blank\">FPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324622-five-prime-readies-75m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Prime readies $75M stock offering</a></h4><ul><li>Five Prime Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a>) <a href=\"https://seekingalpha.com/pr/17054241-five-prime-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences</a> a $75M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>7%&nbsp;</font>after hours on higher-than-normal volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324622\" data-linked=\"Five Prime readies $75M stock offering\" data-tweet=\"$FPRX - Five Prime readies $75M stock offering https://seekingalpha.com/news/3324622-five-prime-readies-75m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324622-five-prime-readies-75m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324621\" data-ts=\"1516741711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAL\" target=\"_blank\">UAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324621-united-continental-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Continental beats by $0.06, beats on revenue</a></h4><ul><li>United Continental (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a>): Q4 EPS of $1.40 <font color='green'>beats by $0.06</font>.</li><li>Revenue of $9.44B (+4.3% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+1.96%</font>.</li><li><a href='https://seekingalpha.com/pr/17054263-united-airlines-reports-fourth-quarter-full-year-2017-performance'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3324621\" data-linked=\"United Continental beats by $0.06, beats on revenue\" data-tweet=\"$UAL - United Continental beats by $0.06, beats on revenue https://seekingalpha.com/news/3324621-united-continental-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3324621-united-continental-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324614\" data-ts=\"1516741425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324614-cree-misses-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree misses by $0.02, beats on revenue</a></h4><ul><li>Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>): Q2 EPS of -$0.01 <font color='red'>misses by $0.02</font>.</li><li>Revenue of $367.87M (+6.0% Y/Y) <font color='green'>beats by $18.25M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/17054236-cree-reports-financial-results-second-quarter-fiscal-year-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3324614\" data-linked=\"Cree misses by $0.02, beats on revenue\" data-tweet=\"$CREE - Cree misses by $0.02, beats on revenue https://seekingalpha.com/news/3324614-cree-misses-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3324614-cree-misses-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324608\" data-ts=\"1516741016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETS\" target=\"_blank\">PETS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324608-plaintiffs-back-off-in-class-action-suit-against-petmed-express-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plaintiffs back off in class action suit against PetMed Express; shares up 5%</a></h4><ul><li>In a <a href=\"https://www.sec.gov/Archives/edgar/data/1040130/000143774918000976/pets20180123_8k.htm\" target=\"_blank\">regulatory filing</a>, PetMed Express (<a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a> <font color='green'>+5.4%</font>) reports that the plaintiffs in a class action lawsuit filed in August and September of last year have voluntarily dismissed the suit without prejudice.</li><li>The suit was filed after equity research outfit Aurelius Value published an&nbsp;<a href=\"http://aureliusvalue.com/research/petmed-exploiting-americas-opioid-epidemic/\" target=\"_blank\">article</a> claiming the company was intentionally selling its pet opioid Tramadol to people.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291623-google-removes-search-ads-petmeds-tramadol-bargain-hunters-move-stock-3-percent\" target=\"_blank\">Google removes search ads for PetMed's Tramadol while bargain hunters move in; stock up 3%</a> (Aug. 24, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291312-petmed-express-continues-slide-14-percent\" target=\"_blank\">PetMed Express continues slide, down 14%</a> (Aug. 23, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324608\" data-linked=\"Plaintiffs back off in class action suit against PetMed Express; shares up 5%\" data-tweet=\"$PETS - Plaintiffs back off in class action suit against PetMed Express; shares up 5% https://seekingalpha.com/news/3324608-plaintiffs-back-off-in-class-action-suit-against-petmed-express-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3324608-plaintiffs-back-off-in-class-action-suit-against-petmed-express-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324602\" data-ts=\"1516740059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGLE\" target=\"_blank\">AGLE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324602-aeglea-bio-sells-off-after-presentation-on-lead-candidate-aeb1102-shares-down-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11%</a></h4><ul><li>Investors in thinly traded nano cap Aeglea BioTherapeutics (<a href='https://seekingalpha.com/symbol/AGLE' title='Aeglea BioTherapeutics'>AGLE</a> <font color='red'>-10.5%</font>) appear to be taking profits after its<font color='green'>&nbsp;88%</font>&nbsp;runup since the first of December.</li><li>Yesterday evening, <a href=\"https://seekingalpha.com/pr/17050821-aeglea-biotherapeutics-present-preclinical-data-2018-keystone-symposia-tumor-metabolism\" target=\"_blank\">data were presented</a> at the Keystone Symposia Tumor Metabolism Conference in Snowbird, UT on how arginine depletion with lead candidate AEB1102 (pegzilarginase) enhanced the anti-tumor activity of a PD-L1 inhibitor.</li><li><a href=\"http://www.aegleabio.com/amino-acid-therapy-research-and-development/#aeb1102\" target=\"_blank\">Pegzilarginase </a>is an arginine degrader derived from human Arginase 1. The company says it has a potential immunogenicity advantage over microbial enzymes because its human origin makes it less likely to provoke an immune response when administered.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324602\" data-linked=\"Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11%\" data-tweet=\"$AGLE - Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11% https://seekingalpha.com/news/3324602-aeglea-bio-sells-off-after-presentation-on-lead-candidate-aeb1102-shares-down-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3324602-aeglea-bio-sells-off-after-presentation-on-lead-candidate-aeb1102-shares-down-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324601\" data-ts=\"1516739840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOS\" target=\"_blank\">MOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324601-mosaicplus-3-bernstein-analyst-says-stock-is-top-pick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mosaic +3% as Bernstein analyst says stock is top pick</a></h4><ul>     <li>Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='green'>+2.8%</font>) is on the move after Bernstein analyst Jonas Oxgaard names the stock as his <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11066175/bernstein-explains-bullish-call-on-mosaic\" target=\"_blank\">top pick for 2018</a>, raising his price target to $44 from $33 and reiterating his Outperform rating.</li>     <li>Oxgaard believes fertilizer prices will be strong in 2018 and expects further strength in the already above-consensus prices for both potash and phosphate, benefiting MOS.</li>     <li>The firm does not see MOS's debt burden as a cause for concern, as the company's credit revolver facility eliminated any short-term liquidity concerns.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324601\" data-linked=\"Mosaic +3% as Bernstein analyst says stock is top pick\" data-tweet=\"$MOS - Mosaic +3% as Bernstein analyst says stock is top pick https://seekingalpha.com/news/3324601-mosaicplus-3-bernstein-analyst-says-stock-is-top-pick?source=tweet\" data-url=\"https://seekingalpha.com/news/3324601-mosaicplus-3-bernstein-analyst-says-stock-is-top-pick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324594\" data-ts=\"1516738667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYME\" target=\"_blank\">ZYME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324594-zymeworks-and-vtv-therapeutics-join-biotech-breakouts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zymeworks and vTv Therapeutics join biotech breakouts</a></h4><ul><li>Zymeworks (<a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks'>ZYME</a> <font color='green'>+19.9%</font>) and vTv Therapeutics (<a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+26.7%</font>), both thinly traded, are showing healthy breakouts on 3x and 6x surges in volume, respectively.</li><li>No particular company-specific news accounts for the action, but biotechs in general are heading north. The SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='green'>+2.2%</font>), for example, has rallied over&nbsp;<font color='green'>9%</font>&nbsp;since Thursday.</li><li>Zymeworks' lead candidate is ZW25, in Phase 1 development for HER2+ cancers. It has collaboration deals with Celgene, Daiichi-Sankyo, Johnson &amp; Johnson, Eli Lilly and Merck.</li><li>Vtv Therapeutics' lead candidate is <a href=\"http://www.vtvtherapeutics.com/pipeline/azeliragon\" target=\"_blank\">azeliragon </a>(TTP488), in Phase 3 development for Alzheimer's disease.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324594\" data-linked=\"Zymeworks and vTv Therapeutics join biotech breakouts\" data-tweet=\"$ZYME $ZYME $VTVT - Zymeworks and vTv Therapeutics join biotech breakouts https://seekingalpha.com/news/3324594-zymeworks-and-vtv-therapeutics-join-biotech-breakouts?source=tweet\" data-url=\"https://seekingalpha.com/news/3324594-zymeworks-and-vtv-therapeutics-join-biotech-breakouts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324591\" data-ts=\"1516737657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNE\" target=\"_blank\">SNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324591-sony-goes-negative-jpmorgan-downgrades-on-phone-sensor-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sony goes negative as JPMorgan downgrades on phone sensor worries</a></h4><ul>   <li>Sony (NYSE:<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a>), in positive ground all day, has slipped to a <a href=\"https://seekingalpha.com/news/3324581-apple-suppliers-move-jpmorgan-says-iphone-x-build-will-weaken\" target=\"_blank\">1% decline</a> after JPMorgan downgraded the stock to Neutral on image sensor weakness (tied in <a href=\"https://seekingalpha.com/news/3324581-apple-suppliers-move-jpmorgan-says-iphone-x-build-will-weaken\" target=\"_blank\">no small part to the iPhone X</a>).</li>    <li>With momentum slowing on the iPhone and high-end smartphones \"clearly hitting a plateau,\" Sony's image sensors will fall on harder demand.</li>    <li>Apple makes up about 50% of total CIS revenue, analyst J.J. Park says, and Sony stock has increasingly moved along with that of Apple and its supply chain names. (h/t Bloomberg)</li>    <li>The firm says iPhone X production would likely fall 50% sequentially, with weakness ongoing through the first half.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324591\" data-linked=\"Sony goes negative as JPMorgan downgrades on phone sensor worries\" data-tweet=\"$SNE - Sony goes negative as JPMorgan downgrades on phone sensor worries https://seekingalpha.com/news/3324591-sony-goes-negative-jpmorgan-downgrades-on-phone-sensor-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3324591-sony-goes-negative-jpmorgan-downgrades-on-phone-sensor-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324588\" data-ts=\"1516737485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324588-petrobras-ceo-parente-says-open-to-staying-beyond-october-election\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras CEO Parente says open to staying beyond October election</a></h4><ul>     <li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='red'>-2%</font>)&nbsp;CEO&nbsp;Pedro Parente says he <a href=\"https://www.bloomberg.com/news/articles/2018-01-23/petrobras-turnaround-ceo-could-consider-staying-past-elections\" target=\"_blank\">could consider staying in the job</a> after Brazil's October presidential election as long as the state-controlled company keeps its independence under the next government.</li>     <li>Although Parente&rsquo;s mandate lasts until March 2019, Brazil&rsquo;s next government could use its majority of PBR voting shares to appoint a new CEO at the start of 2019.</li>     <li>Parente also says the company will meet its $21B target even for asset sales even though it has more than $16B to divest in the remainder of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324588\" data-linked=\"Petrobras CEO Parente says open to staying beyond October election\" data-tweet=\"$PBR - Petrobras CEO Parente says open to staying beyond October election https://seekingalpha.com/news/3324588-petrobras-ceo-parente-says-open-to-staying-beyond-october-election?source=tweet\" data-url=\"https://seekingalpha.com/news/3324588-petrobras-ceo-parente-says-open-to-staying-beyond-october-election\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324586\" data-ts=\"1516737315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324586-technology-top-gainers-losers-of-2_55-pm-1-23-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (1/23/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RVLT' title='Revolution Lighting Technologies, Inc.'>RVLT</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/LOGI' title='Logitech International S.A.'>LOGI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/DAIO' title='Data I/O Corporation'>DAIO</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324586\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (1/23/18)\" data-tweet=\"$RVLT $HMNY $LOGI - Technology - Top Gainers / Losers as of 2.55 pm (1/23/18) https://seekingalpha.com/news/3324586-technology-top-gainers-losers-of-2_55-pm-1-23-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3324586-technology-top-gainers-losers-of-2_55-pm-1-23-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324581\" data-ts=\"1516736673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324581-apple-suppliers-move-after-jpmorgan-says-iphone-x-build-will-weaken\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple, suppliers move after JPMorgan says iPhone X build will weaken</a></h4><ul><li>        JPMorgan sees more signs of weakening Apple iPhone X (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.6%</font>) sales and forecasts build to be down 50% on the quarter.</li><li>                  The drop represents a build decline larger than that of the iPhone 8 and 8 Plus.    </li><li>               Apple suppliers that could move on the news: Skyworks Solutions (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='green'>+0.2%</font>), &nbsp;Cirrus Logic (<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a> <font color='red'>-0.3%</font>), Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> <font color='green'>+0.2%</font>), Qorvo (<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='green'>+1.1%</font>), Finisar (<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='red'>-4.7%</font>), II-VI (<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a> <font color='red'>-1.5%</font>), Lumentum (<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='red'>-4.2%</font>).&nbsp;</li><li>               Sources: Bloomberg First Word and <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a>.&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324534-apple-roundup-iphone-x-sells-29m-units-new-macbook-rumor-foxconn-shift\" target=\"_blank\">Apple roundup: iPhone X sells 29M units, new MacBook rumor, Foxconn shift</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324581\" data-linked=\"Apple, suppliers move after JPMorgan says iPhone X build will weaken\" data-tweet=\"$AAPL $AAPL $SWKS - Apple, suppliers move after JPMorgan says iPhone X build will weaken https://seekingalpha.com/news/3324581-apple-suppliers-move-after-jpmorgan-says-iphone-x-build-will-weaken?source=tweet\" data-url=\"https://seekingalpha.com/news/3324581-apple-suppliers-move-after-jpmorgan-says-iphone-x-build-will-weaken\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>153&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324580\" data-ts=\"1516736382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324580-nomura-reels-in-expectations-on-wynn-resorts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura reels in expectations on Wynn Resorts</a></h4><ul> <li>Nomura Instinet analyst Harry Curtis cautions investors of Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='red'>-0.1%</font>) not to extrapolate the positive update from Steve Wynn on the casino operator's early January EBITDA rate of $5M per day in Macau.</li> <li>\"It wouldn&rsquo;t surprise us if some analysts do not hold adjust Mr. Wynn&rsquo;s bullish $5mn/day comment. We caution that in addition to the positive influence of hold, the first 21 days in a 365 day calendar does not a year make,\" observes Curtis.</li> <li>Curtis expects a normalized EBITDA mark of closer to $4.5M per day.</li> <li>Wynn is rated at Neutral by the firm and assigned a price target of $195 (12.8X EV/EBITDA).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324503-wynn-resorts-back-200\" target=\"_blank\">Wynn Resorts back over $200</a> (Jan. 23)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324580\" data-linked=\"Nomura reels in expectations on Wynn Resorts\" data-tweet=\"$WYNN - Nomura reels in expectations on Wynn Resorts https://seekingalpha.com/news/3324580-nomura-reels-in-expectations-on-wynn-resorts?source=tweet\" data-url=\"https://seekingalpha.com/news/3324580-nomura-reels-in-expectations-on-wynn-resorts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324579\" data-ts=\"1516735823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324579-first-solar-turns-lower-relief-rally-over-tariffs-fades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Solar turns lower as relief rally over tariffs fades</a></h4><ul>     <li>The Solar Energy Industries Association, the main U.S. solar trade group that led the lobbying fight against tariffs, says the Trump administration showed \"<a href=\"https://www.bloomberg.com/news/articles/2018-01-23/solar-group-says-trump-showed-some-restraint-in-tariff-move\" target=\"_blank\">some restraint</a>\" in its decision to slap tariffs as high as 30% on imports of solar cells and modules (<a href=\"https://seekingalpha.com/news/3324318-first-solar-whirlpool-pop-trump-tariff-news\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/news/3324354-solar-names-respond-new-u-s-tariffs\" target=\"_blank\">II</a>, <a href=\"https://seekingalpha.com/news/3324439-solar-stocks-mostly-higher-trump-tariffs-worse\" target=\"_blank\">III</a>), but solar shares are mixed as an early relief rally fades.</li>     <li>The tariff&nbsp;is not as harsh as many had expected and \"<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11065761/chardan-solar-decision-removes-uncertainty-for-sunworks\" target=\"_blank\">removes significant uncertainty</a>\" for the solar industry, and prices already have adjusted in anticipation of the decision so the final action will cause \"little incremental impact\" on prices, says Chardan analyst James McIlree.</li><li>\"Given that some of the proposals had featured tariffs as high as 35%... we see this announcement as a <a href=\"https://www.cnbc.com/2018/01/23/whirlpool-first-solar-shares-soar-after-trumps-approves-tariffs-on-foreign-competitors.html\" target=\"_blank\">positive for module importers</a>  given the quick scale to 15% over four years,\" Cowen analysts say.</li>     <li>A 30% tariff on modules could raise the cost of residential rooftop solar systems by ~4%, the cost of distributed commercial solar projects by 6% and the cost of utility-scale solar projects by 10%, ClearView Energy Partners calculates.</li>     <li>First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='red'>-0.4%</font>), which opened higher as the kind of thin film panels it makes may be exempt from the tariffs, is now in the red.</li>     <li><a href='https://seekingalpha.com/symbol/CAFD' title='8point3 Energy Partners LP'>CAFD</a> <font color='green'>+0.2%</font>, <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-1.4%</font>, <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+5.6%</font>, <a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color='red'>-0.1%</font>, <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='red'>-6.8%</font>, <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+28.7%</font>, <a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='green'>+6%</font>, <a href='https://seekingalpha.com/symbol/SEDG' title='SolarEdge Technologies'>SEDG</a> <font color='green'>+2.8%</font>, <a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a> <font color='green'>+0.3%</font>, <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='red'>-7.4%</font>, <a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a> <font color='green'>+8.8%</font>, <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+7.1%</font>, <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-2.7%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/KWT' title='VanEck Vectors Solar Energy ETF'>KWT</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3324579\" data-linked=\"First Solar turns lower as relief rally over tariffs fades\" data-tweet=\"$FSLR $FSLR $CAFD - First Solar turns lower as relief rally over tariffs fades https://seekingalpha.com/news/3324579-first-solar-turns-lower-relief-rally-over-tariffs-fades?source=tweet\" data-url=\"https://seekingalpha.com/news/3324579-first-solar-turns-lower-relief-rally-over-tariffs-fades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324578\" data-ts=\"1516735781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324578-mattel-and-hasbro-spike-in-afternoon-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel and Hasbro spike in afternoon trading</a></h4><ul><li>Shares of Mattel (<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='green'>+14.4%</font>) and Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='green'>+6%</font>) have spiked on strong volume amid trader chatter of buyout activity.</li><li>The toy companies have been volatile in the past off of M&amp;A talk that hasn't panned out.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324578\" data-linked=\"Mattel and Hasbro spike in afternoon trading\" data-tweet=\"$MAT $MAT $HAS - Mattel and Hasbro spike in afternoon trading https://seekingalpha.com/news/3324578-mattel-and-hasbro-spike-in-afternoon-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3324578-mattel-and-hasbro-spike-in-afternoon-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324574\" data-ts=\"1516734264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324574-energy-materials-top-gainers-losers-of-2-00-pm-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/23/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+-26%</font>. <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='green'>+-10%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+-8%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+-7%</font>. <a href='https://seekingalpha.com/symbol/METC' title='Ramaco'>METC</a> <font color='green'>+-7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='red'>13%</font>. <a href='https://seekingalpha.com/symbol/DWSN' title='Dawson Geophysical Company'>DWSN</a> <font color='red'>12%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='red'>12%</font>. EXXI <font color='red'>8%</font>. <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='red'>8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324574\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/23/2018)\" data-tweet=\"$PVG $TRNX $CDXC - Energy/Materials - Top Gainers / Losers as of 2:00 pm (1/23/2018) https://seekingalpha.com/news/3324574-energy-materials-top-gainers-losers-of-2-00-pm-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324574-energy-materials-top-gainers-losers-of-2-00-pm-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324568\" data-ts=\"1516732930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324568-palo-alto-networksplus-3_5-deutsche-bank-sees-growth-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks +3.5% as Deutsche Bank sees growth ahead</a></h4><ul>   <li>Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>) is <font color='green'>up 3.5%</font> following an upgrade to Buy at Deutsche Bank.</li>    <li>Field checks are positive and overall firewall demand looks to be stabilizing, says analyst Karl Keirstead.</li>    <li>That means further material deceleration is likely out and there should be stable growth or better ahead, he writes. He's boosted the firm's price target to $180 from $160, implying 13% upside from current pricing.</li>    <li>Meanwhile, Fortinet (NASDAQ:<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a>) is <font color='red'>0.5% lower</font> after Deutsche Bank's downgrade to Hold as its checks have gone worse than expected, according to the firm. Shares were down as much as 5%.</li>    <li>Palo Alto has recouped losses from yesterday when <a href=\"https://seekingalpha.com/news/3324066-goldman-sachs-downgrades-palo-alto-shares-minus-1_4-percent\" target=\"_blank\">Goldman Sachs issued a downgrade</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324568\" data-linked=\"Palo Alto Networks +3.5% as Deutsche Bank sees growth ahead\" data-tweet=\"$PANW $PANW $FTNT - Palo Alto Networks +3.5% as Deutsche Bank sees growth ahead https://seekingalpha.com/news/3324568-palo-alto-networksplus-3_5-deutsche-bank-sees-growth-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3324568-palo-alto-networksplus-3_5-deutsche-bank-sees-growth-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324567\" data-ts=\"1516731732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTX\" target=\"_blank\">BTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324567-biotime-perks-up-3-ahead-of-nobelcon14-presention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioTime perks up 3% ahead of NobelCon14 presention</a></h4><ul><li>BioTime (<a href='https://seekingalpha.com/symbol/BTX' title='BioTime, Inc'>BTX</a> <font color='green'>+3.4%</font>) is up on modestly higher volume, breaking through short-term consolidation.</li><li>On Monday, January 29 CFO Russell Skibsted will present a <a href=\"https://seekingalpha.com/pr/17053153-biotime-present-noble-capital-markets-14th-annual-institutional-investor-conference-fort\" target=\"_blank\">corporate overview</a> at NobelCon14 in Fort Lauderdale, FL.&nbsp; A webcast of the event will be available via noble.mediasite.com. A replay will be available in the \"Events and Presentations\" section of the company's website.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324567\" data-linked=\"BioTime perks up 3% ahead of NobelCon14 presention\" data-tweet=\"$BTX $LCTX - BioTime perks up 3% ahead of NobelCon14 presention https://seekingalpha.com/news/3324567-biotime-perks-up-3-ahead-of-nobelcon14-presention?source=tweet\" data-url=\"https://seekingalpha.com/news/3324567-biotime-perks-up-3-ahead-of-nobelcon14-presention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324565\" data-ts=\"1516731246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATUS\" target=\"_blank\">ATUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324565-altice-altice-usa-climbing-barclays-lauds-separation-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altice, Altice USA climbing as Barclays lauds separation plan</a></h4><ul>    <li>Altice USA (<a href=\"http://seekingalpha.com/symbol/ATUS\" target=\"_blank\">ATUS</a> <font color='green'>+4.9%</font>) will benefit from shaking off its European parent via a spin-off, Barclays says amid an upgrade to Overweight.</li>    <li>Not only will other cablecos interested in M&amp;A have an easier time engaging with the U.S. arm, but the company gets more credibility for its margin guidance from leverage reduction, analyst Kannan Venkateshwar writes. (h/t Bloomberg)</li>    <li>Barclays also boosted the parent (<a href=\"http://seekingalpha.com/symbol/ALLVF\" target=\"_blank\">ALLVF</a> <font color='green'>+5.1%</font>) to Overweight as the company has a \"range of options,\" including monetizing French content assets and towers in France and Portugal, along with consolidation of the mobile market in France. Shares are <font color='green'>up 4.4%</font> in Amsterdam.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324565\" data-linked=\"Altice, Altice USA climbing as Barclays lauds separation plan\" data-tweet=\"$ATUS $ATUS $ALLVF - Altice, Altice USA climbing as Barclays lauds separation plan https://seekingalpha.com/news/3324565-altice-altice-usa-climbing-barclays-lauds-separation-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3324565-altice-altice-usa-climbing-barclays-lauds-separation-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324564\" data-ts=\"1516731240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324564-spectrum-pharma-heads-north-ahead-of-nobelcon14-presentation-shares-ahead-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma heads north ahead of NobelCon14 presentation; shares ahead 6%</a></h4><ul><li>Spectrum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+5.7%</font>) is up on modestly higher volume. Shares have jumped&nbsp;<font color='green'>16%</font>&nbsp;this week.</li><li>On Tuesday, January 30, the company (presumably CEO Joseph Turgeon) will present a <a href=\"https://seekingalpha.com/pr/17053151-spectrum-pharmaceuticals-present-corporate-update-noble-capital-markets-fourteenth-annual\" target=\"_blank\">corporate overview</a> at NobelCon14 in Fort Lauderdale, FL.</li><li>Consensus view for Q4 is a loss/share of ($0.26) on revenue of $32.9M. 2018 consensus is a loss/share of ($0.98) on revenue of $128.6M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324564\" data-linked=\"Spectrum Pharma heads north ahead of NobelCon14 presentation; shares ahead 6%\" data-tweet=\"$SPPI - Spectrum Pharma heads north ahead of NobelCon14 presentation; shares ahead 6% https://seekingalpha.com/news/3324564-spectrum-pharma-heads-north-ahead-of-nobelcon14-presentation-shares-ahead-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3324564-spectrum-pharma-heads-north-ahead-of-nobelcon14-presentation-shares-ahead-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324563\" data-ts=\"1516730950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBI\" target=\"_blank\">MBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324563-puerto-rico-exposure-good-thing-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puerto Rico exposure a good thing today</a></h4><ul><li>Helping sentiment <a href=\"https://seekingalpha.com/news/3324530-popular-shows-post-hurricane-resilience-shares-nearly-7-percent\" target=\"_blank\">is a big Q4 earnings beat</a> from Popular (it's&nbsp;<font color='green'>up 7%</font>) and the Governor's promise <a href=\"https://www.reuters.com/article/us-puertorico-power-prepa/puerto-rico-to-sell-off-crippled-power-utility-prepa-idUSKBN1FB31M\" target=\"_blank\">to move forward</a> with plans to privatize the troubled power utility, Prepa.</li><li>MBIA (<a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a> <font color='green'>+6.3%</font>), Evertec (<a href='https://seekingalpha.com/symbol/EVTC' title='EVERTEC'>EVTC</a> <font color='green'>+7.6%</font>), Ambac (<a href='https://seekingalpha.com/symbol/AMBC' title='Ambac Financial'>AMBC</a> <font color='green'>+4.9%</font>), Assured Guaranty (<a href='https://seekingalpha.com/symbol/AGO' title='Assured Guaranty Ltd.'>AGO</a> <font color='green'>+2.1%</font>), OFG Bancorp (<a href='https://seekingalpha.com/symbol/OFG' title='OFG Bancorp'>OFG</a> <font color='green'>+4.4%</font>), First Bancorp (<a href='https://seekingalpha.com/symbol/FBP' title='First BanCorp'>FBP</a> <font color='green'>+4.9%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3324563\" data-linked=\"Puerto Rico exposure a good thing today\" data-tweet=\"$MBI $MBI $EVTC - Puerto Rico exposure a good thing today https://seekingalpha.com/news/3324563-puerto-rico-exposure-good-thing-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3324563-puerto-rico-exposure-good-thing-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324561\" data-ts=\"1516730595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRNA\" target=\"_blank\">DRNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324561-dicerna-pharma-perks-up-ahead-of-nobelcon14-presentation-shares-ahead-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dicerna Pharma perks up ahead of NobelCon14 presentation; shares ahead 12%</a></h4><ul><li>Thinly traded micro cap Dicerna Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+12.2%</font>) is up on triple normal volume. Shares have rallied&nbsp;<font color='green'>23%</font>&nbsp;this week.</li><li>On Tuesday, January 30 CEO Douglas Fambrough, Ph.D., will deliver a <a href=\"http://investors.dicerna.com/releasedetail.cfm?ReleaseID=1054974\" target=\"_blank\">corporate overview</a> at NobelCon14 in Fort Lauderdale, FL. A live webcast will be accessible through the company's website.</li><li>The company's lead candidate is DCR-PHXC, in Phase 1 development for primary hyperoxaluria, a group of rare inherited disorders that leads to kidney failure.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317019-early-stage-study-underway-assessing-dicernas-lead-candidate-rare-liver-disorder\" target=\"_blank\">Early-stage study underway assessing Dicerna's lead candidate in rare liver disorder</a> (Dec. 7, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324561\" data-linked=\"Dicerna Pharma perks up ahead of NobelCon14 presentation; shares ahead 12%\" data-tweet=\"$DRNA - Dicerna Pharma perks up ahead of NobelCon14 presentation; shares ahead 12% https://seekingalpha.com/news/3324561-dicerna-pharma-perks-up-ahead-of-nobelcon14-presentation-shares-ahead-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3324561-dicerna-pharma-perks-up-ahead-of-nobelcon14-presentation-shares-ahead-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324558\" data-ts=\"1516730458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324558-financials-top-5-gainers-losers-of-1-00-pm-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (1/23/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BPOP' title='Popular, Inc.'>BPOP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WRLD' title='World Acceptance Corporation'>WRLD</a> <font color='green'>+6%</font>.<a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties'>IIPR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WVFC' title='WVS Financial Corp.'>WVFC</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324558\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (1/23/2018)\" data-tweet=\"$BPOP $WRLD $MBI - Financials - Top 5 Gainers / Losers as of 1:00 PM (1/23/2018) https://seekingalpha.com/news/3324558-financials-top-5-gainers-losers-of-1-00-pm-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324558-financials-top-5-gainers-losers-of-1-00-pm-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324555\" data-ts=\"1516730030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324555-midday-gainers-losers-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (1/23/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/RVLT' title='Revolution Lighting Technologies, Inc.'>RVLT</a> <font color='green'>+16%</font>. ARGS <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/RMD' title='ResMed Inc.'>RMD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ACMR' title='ACM Research, Inc.'>ACMR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/JMBA' title='Jamba, Inc.'>JMBA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EDU' title='New Oriental Education & Technology Group Inc.'>EDU</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324555\" data-linked=\"Midday Gainers / Losers (1/23/2018)\" data-tweet=\"$RGSE $RVLT $ARGSQ - Midday Gainers / Losers (1/23/2018) https://seekingalpha.com/news/3324555-midday-gainers-losers-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324555-midday-gainers-losers-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324554\" data-ts=\"1516729574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324554-buying-picks-up-in-vistagen-ahead-of-nobelcon14-presentation-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buying picks up in VistaGen ahead of NobelCon14 presentation; shares up 10%</a></h4><ul><li>Nano cap VistaGen Therapeutics (<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='green'>+10.2%</font>) is up again today on modestly higher volume. Shares have perked up over&nbsp;<font color='green'>20%</font>&nbsp;this week.</li><li>On Monday, January 29, CEO Shawn Singh will <a href=\"https://www.vistagen.com/news-media/press-releases/detail/80/vistagen-therapeutics-to-provide-update-on-phase-2-study\" target=\"_blank\">update investors</a> on the Phase 2 study of lead candidate AV-101 in major depressive disorder &#40;MDD&#41; at NobelCon14 in Fort Lauderdale, FL. He will also outline key initiatives for 2018.</li><li>The webcast of the event will be available the next day in <a href=\"https://ir.vistagen.com/\" target=\"_blank\">investor relations</a> section of the company's website.</li><li><a href=\"http://www.vistagen.com/?page_id=11\" target=\"_blank\">AV-101</a>&nbsp;is an orally available central nervous system &#40;CNS&#41; prodrug that is converted in the brain by cells called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Astrocyte\" target=\"_blank\">astrocytes&nbsp;</a>into its active metabolite, 7-chlorokynurenic acid (7-CI-KYNA), a highly selective antagonist of certain receptors &#40;NMDA&#41;&nbsp;that play key roles in neurodegenerative diseases like epilepsy, MDD and neuropathic pain.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324554\" data-linked=\"Buying picks up in VistaGen ahead of NobelCon14 presentation; shares up 10%\" data-tweet=\"$VTGN - Buying picks up in VistaGen ahead of NobelCon14 presentation; shares up 10% https://seekingalpha.com/news/3324554-buying-picks-up-in-vistagen-ahead-of-nobelcon14-presentation-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3324554-buying-picks-up-in-vistagen-ahead-of-nobelcon14-presentation-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324551\" data-ts=\"1516728869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324551-ft-qualcomm-facing-potential-2b-eu-fine-over-apple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: Qualcomm facing potential $2B EU fine over Apple</a></h4><ul><li>        EU antitrust regulators will sanction Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) for hurting competition by paying Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) to use its chips exclusively, according to <a href=\"https://www.ft.com/content/fc712538-004a-11e8-9650-9c0ad2d7c5b5\" target=\"_blank\">FT</a>.</li><li>                  Qualcomm paid Apple to buy all of its communication chipsets from 2011 to 2016.    </li><li>               EU fines for such discretions are capped at 10% of a company&rsquo;s annual turnover, which would put Qualcomm&rsquo;s maximum payment at about $2B.&nbsp;</li><li>               The fine would give Apple power in its ongoing legal battles against Qualcomm for &ldquo;exclusionary tactics and excessive royalties&rdquo; and weaken Qualcomm as it tries to fight off the unsolicited bid from Broadcom. &nbsp;&nbsp;</li><li>                  EU regulators will reportedly announce the sanction tomorrow.&nbsp;&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3324407-qualcomm-shareholders-block-broadcom-picks-regulatory-concerns\" target=\"_blank\">Qualcomm: Shareholders should block Broadcom picks on regulatory concerns</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324551\" data-linked=\"FT: Qualcomm facing potential $2B EU fine over Apple\" data-tweet=\"$QCOM $QCOM $AAPL - FT: Qualcomm facing potential $2B EU fine over Apple https://seekingalpha.com/news/3324551-ft-qualcomm-facing-potential-2b-eu-fine-over-apple?source=tweet\" data-url=\"https://seekingalpha.com/news/3324551-ft-qualcomm-facing-potential-2b-eu-fine-over-apple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324548\" data-ts=\"1516728359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVG\" target=\"_blank\">PVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324548-pretium-resourcesminus-26-brucejack-production-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pretium Resources -26% as Brucejack production disappoints</a></h4><ul>     <li>Pretium Resources (<a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='red'>-26.8%</font>) plunges after reporting <a href=\"https://seekingalpha.com/pr/17053047-brucejack-mine-production-update-2018-guidance\" target=\"_blank\">weaker than expected Q4 production</a> at its flagship Brucejack gold mine in British Columbia.</li>     <li>PVG says Brucejack produced 70.3K oz. of gold in Q4, well below 82.2K oz. produced in Q3, which was the first full quarter of ramping up production at the mine; Q4's 5.8% gold recovery rate trailed the 96.2% average gold recovery rate for the first six months of production ramp-up.</li>     <li>PVG, which now expects steady state gold production to be achieved in mid-to-late 2018, forecasts H1 2018 gold production at Brucejack of 150K-200K oz., for total first year (starting July 1, 2017) ramp-up gold production of 302K-352K oz.</li>     <li>The company sees H1 all-in sustaining costs of $700-$900/oz. of gold sold, after AISC came in at $788/oz. in Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324548\" data-linked=\"Pretium Resources -26% as Brucejack production disappoints\" data-tweet=\"$PVG - Pretium Resources -26% as Brucejack production disappoints https://seekingalpha.com/news/3324548-pretium-resourcesminus-26-brucejack-production-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3324548-pretium-resourcesminus-26-brucejack-production-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324546\" data-ts=\"1516728127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324546-medicines-cos-inclisiran-orphan-drug-in-u-s-for-hofh-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Medicines Co&#39;s inclisiran an Orphan Drug in U.S. for HoFH; shares up 3%</a></h4><ul><li>The FDA <a href=\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=618017\" target=\"_blank\">designates </a>The Medicines Company's (<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='green'>+2.5%</font>) inclisiran an Orphan Drug for the treatment of <a href=\"https://thefhfoundation.org/about-fh/what-is-fh\" target=\"_blank\">homozygous familial hypercholesterolemia</a> (HoFH), an inherited disorder characterized by extremely high levels of \"bad\" cholesterol in the blood.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li><li>Phase 3-stage inclisiran, being co-developed with Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+5.4%</font>),&nbsp;is an investigational GalNAc-conjugated RNAi therapeutic targeting PCSK9, a protein regulator of LDL receptor metabolism.&nbsp;It lowers bad cholesterol (LDL-C) by turning off PCSK9 synthesis in the liver.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292152-alnylam-medicines-companys-inclisiran-shows-significant-treatment-effect-mid-stage-study\" target=\"_blank\">Alnylam and The Medicines Company's inclisiran shows significant treatment effect in mid-stage study</a> (Aug. 28, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324546\" data-linked=\"The Medicines Co&#39;s inclisiran an Orphan Drug in U.S. for HoFH; shares up 3%\" data-tweet=\"$MDCO $MDCO $ALNY - The Medicines Co&#39;s inclisiran an Orphan Drug in U.S. for HoFH; shares up 3% https://seekingalpha.com/news/3324546-medicines-cos-inclisiran-orphan-drug-in-u-s-for-hofh-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3324546-medicines-cos-inclisiran-orphan-drug-in-u-s-for-hofh-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324542\" data-ts=\"1516727423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNET\" target=\"_blank\">CNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324542-chinanet-online-jumps-announces-new-blockchain-joint-venture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChinaNet Online jumps as it announces new blockchain joint venture</a></h4><ul>   <li>ChinaNet Online Holdings (<a href=\"http://seekingalpha.com/symbol/CNET\" target=\"_blank\">CNET</a> <font color='green'>+16.3%</font>) is on the move again on a blockchain headline, as the company announces a <a href=\"https://seekingalpha.com/pr/17053451-chinanet-online-holdings-announces-new-joint-venture-blockchain-technology-development\" target=\"_blank\">new joint venture</a> around the technology.</li>    <li>It's entered a JV with Wuxi Jingtum and Ford Tree Blockchain Technology to work research and development in the burgeoning area.</li>    <li>ChinaNet will be the controlling shareholder in the JV, to be registered in early February.</li>    <li>Ford Tree will be responsible for creating and reviewing the operating model for blockchain applications in the venture.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321206-chinanet-online-plus-145-percent-latest-ring-bell-blockchain-pivot\" target=\"_blank\">ChinaNet Online +145%, latest to ring bell on blockchain pivot</a> (Jan. 04 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324542\" data-linked=\"ChinaNet Online jumps as it announces new blockchain joint venture\" data-tweet=\"$CNET - ChinaNet Online jumps as it announces new blockchain joint venture https://seekingalpha.com/news/3324542-chinanet-online-jumps-announces-new-blockchain-joint-venture?source=tweet\" data-url=\"https://seekingalpha.com/news/3324542-chinanet-online-jumps-announces-new-blockchain-joint-venture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324539\" data-ts=\"1516727176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324539-fate-therapeutics-adds-to-up-move-shares-ahead-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate Therapeutics adds to up move, shares ahead 16%</a></h4><ul><li>Fate Therapeutics (<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a> <font color='green'>+15.8%</font>) is up again on double normal volume. Shares have rallied&nbsp;<font color='green'>111%&nbsp;</font>since mid-December.</li><li>Last month, the company reported positive preliminary results from a Phase 1/2 clinical trial assessing programmed cellular immunotherapy <a href=\"http://fatetherapeutics.com/pipeline/immuno-regulation-candidates/protmune/\" target=\"_blank\">ProTmune </a>in blood cancer patients.</li><li>Its lead I-O candidate is Phase 1-stage <a href=\"http://fatetherapeutics.com/pipeline/immuno-oncology-candidates/fate-nk100/\" target=\"_blank\">Fate-NK100</a>, a donor-derived adaptive memory natural killer cell therapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317783-fate-therapeutics-protmune-shows-positive-effect-early-stage-study-shares-5-percent\" target=\"_blank\">Fate Therapeutics' ProTmune shows positive effect in early-stage study; shares up 5%</a> (Dec. 12, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324539\" data-linked=\"Fate Therapeutics adds to up move, shares ahead 16%\" data-tweet=\"$FATE - Fate Therapeutics adds to up move, shares ahead 16% https://seekingalpha.com/news/3324539-fate-therapeutics-adds-to-up-move-shares-ahead-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3324539-fate-therapeutics-adds-to-up-move-shares-ahead-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324536\" data-ts=\"1516726453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATI\" target=\"_blank\">ATI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324536-alegheny-techplus-5-following-strong-q4-optimistic-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alegheny Tech +5% following strong Q4, optimistic outlook</a></h4><ul>     <li>Allegheny Technologies (<a href='https://seekingalpha.com/symbol/ATI' title='Allegheny Technologies Incorporated'>ATI</a> <font color='green'>+5.4%</font>) jumps to a 52-week high after <a href=\"https://seekingalpha.com/news/3324400-allegheny-technologies-beats-0_17-beats-revenue\" target=\"_blank\">Q4 earnings</a> easily beat analyst expectations, with improved Y/Y performance in both its High Performance Materials &amp; Components and Flat Rolled Products business segments.</li><li>ATI says continued strong sales of next-generation jet engine products, which rose 26% Y/Y, drove Q4 HPMC segment operating profit margins to 12.7% of sales, while the FRP business generated more than $22M operating profit, or nearly 6% of sales, for the segment's best quarter in five years.</li>     <li>For 2018, the company expects continued revenue growth and operating margin improvement in HPMC segment and for FRP to build on operational improvements and product mix benefits achieved in 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324536\" data-linked=\"Alegheny Tech +5% following strong Q4, optimistic outlook\" data-tweet=\"$ATI - Alegheny Tech +5% following strong Q4, optimistic outlook https://seekingalpha.com/news/3324536-alegheny-techplus-5-following-strong-q4-optimistic-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3324536-alegheny-techplus-5-following-strong-q4-optimistic-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324534\" data-ts=\"1516726147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324534-apple-roundup-iphone-x-sells-29m-units-new-macbook-rumor-foxconn-shift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple roundup: iPhone X sells 29M units, new MacBook rumor, Foxconn shift</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) shipped 29M iPhone X units in CY17 Q4 (Apple&rsquo;s Q1 FY18), according to <a href=\"https://9to5mac.com/2018/01/23/iphone-x-sales-canalys/\" target=\"_blank\">Canalys estimates</a>, and 7M were shipped in China.</li><li>               Canalys says the 29M units are slightly below expectations likely due to the initial supply constraints and splitting the launch with the iPhone 8 and iPhone X.&nbsp;</li><li>               Buyers didn&rsquo;t balk at the premium price tag due to financing plans and trade-in programs.&nbsp;</li><li>               Strong sales in older iPhone models helped Apple hedged the risk of launching three new phones last year.&nbsp;</li><li>               New MacBook: <a href=\"http://www.digitimes.com/news/a20180123PD202.html\" target=\"_blank\">Digitimes</a> reports that Apple will release an entry-level, 13-inch MacBook in 2H18.&nbsp;</li><li>               Sources say touch panel maker General Interface Solutions will supply LCM for the product after becoming a MacBook supplier in CY17 Q4. &nbsp;&nbsp;</li><li>               Supplier shift: Foxconn (<a href='https://seekingalpha.com/symbol/HNHAF' title='Hon Hai Precision Industry Co. Ltd.'>OTCPK:HNHAF</a>, HNHAY) could add its iPhone unit to a <a href=\"https://asia.nikkei.com/Markets/Capital-Markets/Foxconn-may-add-iPhone-unit-to-new-Shanghai-spinoff-sources\" target=\"_blank\">new Shanghai spinoff</a> called Foxconn Industrial Internet, which will house its networking services and cloud computing operations.&nbsp;</li><li>               Shareholders need to approve the spinoff at the shareholder meeting on January 31.&nbsp;</li><li>Apple share are&nbsp;<font color='green'>up 1.1%</font>.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324498-apples-homepod-smart-speaker-launches-feb-9\" target=\"_blank\">Apple's HomePod smart speaker launches Feb. 9</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324534\" data-linked=\"Apple roundup: iPhone X sells 29M units, new MacBook rumor, Foxconn shift\" data-tweet=\"$AAPL $AAPL $HNHAF - Apple roundup: iPhone X sells 29M units, new MacBook rumor, Foxconn shift https://seekingalpha.com/news/3324534-apple-roundup-iphone-x-sells-29m-units-new-macbook-rumor-foxconn-shift?source=tweet\" data-url=\"https://seekingalpha.com/news/3324534-apple-roundup-iphone-x-sells-29m-units-new-macbook-rumor-foxconn-shift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324530\" data-ts=\"1516725114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPOP\" target=\"_blank\">BPOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324530-popular-shows-post-hurricane-resilience-shares-up-nearly-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Popular shows post-hurricane resilience; shares up nearly 7%</a></h4><ul><li>Popular (NASDAQ:<a href='https://seekingalpha.com/symbol/BPOP' title='Popular, Inc.'>BPOP</a>) bull <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=bbbhek-b\" target=\"_blank\">Mark Palmer from BTIG</a> says that while the bank continues to try to reopen branches and ATMs post-storm, Q4 results were mostly benign.</li><li>Adjusted EPS of $0.65 was well ahead of consensus $0.50, with net interest income of $387.2M topping Palmer's expectations. Provisions of $70M were less than anticipated. The revenue impact from the hurricanes of $20M was within the guided range of $5M-$30M.</li><li>As for tax reform, the bank did have to take a $168M write-down to its DTA, pushing tangible book value down $1.77 per share to $43.02. The bank's effective tax rate going forward, however, should dip to 21%-24% from the mid-high 20% area.</li><li>Palmer reiterates his Buy rating and $46 price target.</li><li>Shares&nbsp;<font color='green'>up 6.8%</font>&nbsp;to $40.99.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324429-popular-beats-net-interest-income\" target=\"_blank\">Popular beats on net interest income</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324530\" data-linked=\"Popular shows post-hurricane resilience; shares up nearly 7%\" data-tweet=\"$BPOP - Popular shows post-hurricane resilience; shares up nearly 7% https://seekingalpha.com/news/3324530-popular-shows-post-hurricane-resilience-shares-up-nearly-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3324530-popular-shows-post-hurricane-resilience-shares-up-nearly-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324525\" data-ts=\"1516724315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XXII\" target=\"_blank\">XXII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324525-short-seller-takes-aim-22nd-century-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Short seller takes aim at 22nd Century Group</a></h4><ul> <li>Keep an eye on 22nd Century Group (<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='green'>+4.1%</font>) after an <a href=\"http://thestreetsweeper.org/undersurveillance/Smokin__22nd_Century__XXII__Will_Get_Crushed\" target=\"_blank\">investor alert</a> was posted by The StreetSweeper.</li> <li>The scathing article on XXII from the short seller includes the following conclusion.</li> <li>\"XXII looks like a massively overpriced, glorified black-and-white TV. The company is not the half-billion-dollar entity suggested by the stock market valuation. The company is irrelevant in a dying market and, to make matters worse, its supposed catalyst is about to go up in smoke.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324525\" data-linked=\"Short seller takes aim at 22nd Century Group\" data-tweet=\"$XXII - Short seller takes aim at 22nd Century Group https://seekingalpha.com/news/3324525-short-seller-takes-aim-22nd-century-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3324525-short-seller-takes-aim-22nd-century-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>117&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324489\" data-ts=\"1516723567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324489-healthcare-top-5-gainers-losers-of-11-00-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/23/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RMD' title='ResMed Inc.'>RMD</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+12%</font>. ARGS <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IRMD' title='iRadimed Corp.'>IRMD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324489\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/23/2018)\" data-tweet=\"$RMD $AMRN $ARGSQ - Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/23/2018) https://seekingalpha.com/news/3324489-healthcare-top-5-gainers-losers-of-11-00-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324489-healthcare-top-5-gainers-losers-of-11-00-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324521\" data-ts=\"1516723081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324521-base-metal-miners-tumble-copper-falls-on-surging-inventories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Base metal miners tumble as copper falls on surging inventories</a></h4><ul>     <li>Base metal mining companies including Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-3.4%</font>) and Teck Resources (<a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-2.5%</font>) are smacked as copper prices fell after inventories surged the most in 10 months.</li><li>Bloomberg analyst Andrew Cosgrove foresees more sideways to downward movement in the short run, with key catalysts  including select physical market indicators remaining soft, better output  visibility from miners as a result of earnings season and weaker  seasonal demand in China.</li><li>Iron ore miners such as Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-4.5%</font>) and Cleveland-Cliffs (<a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-2%</font>) also are lower amid falling prices, as steelmakers  in China, facing a decline in profitability, switch back to using more  lower-grade material, cutting into demand for higher-quality ore.</li><li>Also: <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='red'>-1.9%</font>, <a href='https://seekingalpha.com/symbol/SCCO' title='Southern Copper Corporation'>SCCO</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-1.2%</font>.</li><li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324521\" data-linked=\"Base metal miners tumble as copper falls on surging inventories\" data-tweet=\"$FCX $FCX $TECK - Base metal miners tumble as copper falls on surging inventories https://seekingalpha.com/news/3324521-base-metal-miners-tumble-copper-falls-on-surging-inventories?source=tweet\" data-url=\"https://seekingalpha.com/news/3324521-base-metal-miners-tumble-copper-falls-on-surging-inventories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324518\" data-ts=\"1516722820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324518-goprominus-3_8-on-analyst-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro -3.8% on analyst downgrade</a></h4><ul><li>        Morgan Stanley downgrades GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) from Equal Weight to Underweight and lowers the price target from $9.50 to $5 (nearly 21% downside on yesterday&rsquo;s close.)</li><li>               Analyst Yuuji Anderson says the market gives too much credit to the company&rsquo;s strategic value since it has limited earnings power.</li><li>               Anderson expects negative trends to continue into 2019 since camera usability isn&rsquo;t improving at a fast rate.&nbsp;</li><li>               Source: Bloomberg First Word. &nbsp;&nbsp;&nbsp;</li><li>                  GoPro shares are&nbsp;<font color='red'>down 3.8%</font>&nbsp;to $6.06.   &nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3324518\" data-linked=\"GoPro -3.8% on analyst downgrade\" data-tweet=\"$GPRO - GoPro -3.8% on analyst downgrade https://seekingalpha.com/news/3324518-goprominus-3_8-on-analyst-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3324518-goprominus-3_8-on-analyst-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324513\" data-ts=\"1516722570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBLN\" target=\"_blank\">OBLN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324513-obalon-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obalon shares halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended trading</a> in Obalon Therapeutics (<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a>) pending the release of news, certainly related to its canceled stock offering. Shares will resume trading at 11:00 am ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324478-obalon-therapeutics-cancels-stock-offering-alleged-improper-q4-revenue-recognition\" target=\"_blank\">Obalon Therapeutics cancels stock offering on alleged improper Q4 revenue recognition</a> (Jan. 23)</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>6%</font>&nbsp;on resumption of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324513\" data-linked=\"Obalon shares halted pending news\" data-tweet=\"$OBLN - Obalon shares halted pending news https://seekingalpha.com/news/3324513-obalon-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3324513-obalon-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324501\" data-ts=\"1516720181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSM\" target=\"_blank\">INSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324501-insmed-down-9-on-convertible-debt-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insmed down 9% on convertible debt offering</a></h4><ul><li>Insmed (<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='red'>-8.7%</font>) slips on modestly higher volume on the heels of its announced $300M convertible debt offering. Price and terms have yet to be released.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324255-insmed-launches-300m-convertible-debt-offering\" target=\"_blank\">Insmed launches $300M convertible debt offering</a> (Jan. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324501\" data-linked=\"Insmed down 9% on convertible debt offering\" data-tweet=\"$INSM - Insmed down 9% on convertible debt offering https://seekingalpha.com/news/3324501-insmed-down-9-on-convertible-debt-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3324501-insmed-down-9-on-convertible-debt-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324498\" data-ts=\"1516719822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324498-apples-homepod-smart-speaker-launches-feb-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple&#39;s HomePod smart speaker launches Feb. 9</a></h4><ul><li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) will launch its Siri-enabled HomePod smart speaker in stores on <a href=\"https://seekingalpha.com/pr/17053448-homepod-arrives-february-9-available-order-friday\" target=\"_blank\">February 9</a>.</li><li>Preorders begin January 26 in the US, UK, and Australia. The speaker will hit France and Germany in the spring.</li><li>HomePod was originally scheduled for an early December release ahead of the holiday shopping season.</li><li>The $349 HomePod will compete with lower cost devices from market leaders Amazon and Google. Apple will compete with high-end speaker brand Sonos on the audio-focused side of the market.</li><li>Apple shares are&nbsp;<font color='green'>up 0.6%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313270-apple-homepod-launch-delayed-next-year\" target=\"_blank\">Apple HomePod launch delayed until next year</a> (Nov. 17, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313851-bloomberg-apple-plans-ship-4m-homepod-units-next-year\" target=\"_blank\">Bloomberg: Apple plans to ship 4M HomePod units next year</a> (Nov. 21, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321386-wsj-apple-product-delays-doubled-ceo-cook\" target=\"_blank\">WSJ: Apple product delays doubled under CEO Cook</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324498\" data-linked=\"Apple&#39;s HomePod smart speaker launches Feb. 9\" data-tweet=\"$AAPL $SONO - Apple&#39;s HomePod smart speaker launches Feb. 9 https://seekingalpha.com/news/3324498-apples-homepod-smart-speaker-launches-feb-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3324498-apples-homepod-smart-speaker-launches-feb-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>176&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324497\" data-ts=\"1516719810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMD\" target=\"_blank\">RMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324497-fq2-beat-propels-resmed-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FQ2 beat propels ResMed, up 14%</a></h4><ul><li>ResMed (<a href='https://seekingalpha.com/symbol/RMD' title='ResMed Inc.'>RMD</a> <font color='green'>+14.3%</font>) is up in early trading on 30% higher volume after posting better-than-expected fiscal Q2 results yesterday after the close.</li><li>Consensus view for calendar Q1 (fiscal Q3) is EPS of $0.77 on revenues of $563M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324277-resmed-fq2-revenues-13-percent-eps-87-percent-cash-flow-5-percent\" target=\"_blank\">ResMed FQ2 revenues up 13%; EPS down 87%; cash flow up 5%</a> (Jan. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324247-resmed-beats-0_22-beats-revenue\" target=\"_blank\">ResMed beats by $0.22, beats on revenue</a> (Jan. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324497\" data-linked=\"FQ2 beat propels ResMed, up 14%\" data-tweet=\"$RMD - FQ2 beat propels ResMed, up 14% https://seekingalpha.com/news/3324497-fq2-beat-propels-resmed-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3324497-fq2-beat-propels-resmed-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324492\" data-ts=\"1516719395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRB\" target=\"_blank\">HRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324492-h-and-r-blockplus-5-after-updating-on-tax-reform-impact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H&amp;R Block +5% after updating on tax reform impact</a></h4><ul> <li>H&amp;R Block (<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a> <font color='green'>+5%</font>) breaks higher after updating on the impact of new tax laws.</li> <li>Tax reform update:&nbsp;\"With respect to corporate income taxes, the Company is expecting an annual effective tax rate of approximately 8% to 12% for FY18, comparing favorably to the annual effective tax rate for FY17 of 33.1%. A significant portion of the items generating the tax benefit in FY18 are related to the Tax Legislation becoming effective during FY18 and are not expected to recur. Starting in FY19, the Company currently estimates its annual effective tax rate will be approximately 23% to 25%.\"</li> <li><a href=\"https://seekingalpha.com/filing/3839496\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3324492\" data-linked=\"H&amp;R Block +5% after updating on tax reform impact\" data-tweet=\"$HRB - H&amp;R Block +5% after updating on tax reform impact https://seekingalpha.com/news/3324492-h-and-r-blockplus-5-after-updating-on-tax-reform-impact?source=tweet\" data-url=\"https://seekingalpha.com/news/3324492-h-and-r-blockplus-5-after-updating-on-tax-reform-impact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324488\" data-ts=\"1516719063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324488-creeminus-1_6-on-analyst-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree -1.6% on analyst downgrade</a></h4><ul><li>        ROTH Capital <a href=\"https://www.streetinsider.com/Analyst+Comments/Roth+Capital+Downgrades+Cree+%28CREE%29+to+Neutral/13711608.html\" target=\"_blank\">downgrades</a> Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) from Buy to Neutral with a $35 price target, which is a 4.6% downside on yesterday&rsquo;s closing price.</li><li>               Analyst Craig Irwin cites the fact that Cree will &ldquo;generate a larger portion of FY18 gross margins from SiC wafer sales&rdquo; and the entry of new wafer suppliers will add pressure to the market. &nbsp;&nbsp;</li><li>               Cree shares are&nbsp;<font color='red'>down 1.6%</font>&nbsp;to $36.10.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3324488\" data-linked=\"Cree -1.6% on analyst downgrade\" data-tweet=\"$CREE - Cree -1.6% on analyst downgrade https://seekingalpha.com/news/3324488-creeminus-1_6-on-analyst-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3324488-creeminus-1_6-on-analyst-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324486\" data-ts=\"1516718715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324486-biolinerxs-lead-oncology-candidate-blminus-8040-shows-encouraging-action-in-preclinical-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx&#39;s lead oncology candidate BL-8040 shows encouraging action in preclinical study; shares ahead 5%</a></h4><ul><li>BioLIneRx (<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color='green'>+4.7%</font>) <a href=\"https://seekingalpha.com/pr/17053343-biolinerx-presents-preclinical-data-asco-sitc-showing-blminus-8040-prolongs-survival\" target=\"_blank\">announces </a>positive preclinical data on lead cancer candidate BL-8040. The results will be presented at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco.</li><li>Results from a mouse model showed treatment with BL-8040, in combination with a cancer vaccine that primes the immune system against the tumor, significantly enhanced the anti-tumor response compared to either agent administered alone.</li><li><a href=\"http://www.biolinerx.com/default.asp?pageid=98&amp;itemid=41\" target=\"_blank\">BL-8040</a>&nbsp;is a short peptide for the treatment of acute myeloid leukemia, solid tumors and certain hematological indications. It functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297558-biolinerx-initiates-phase-1b-2-trial-blminus-8040-aml-immunotherapy-collaboration\" target=\"_blank\">BioLineRx initiates Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration</a> (Sept. 26, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319597-biolinerx-launches-late-stage-study-blminus-8040\" target=\"_blank\">BioLineRx launches late-stage study of BL-8040</a> (Dec. 21, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324486\" data-linked=\"BioLineRx&#39;s lead oncology candidate BL-8040 shows encouraging action in preclinical study; shares ahead 5%\" data-tweet=\"$BLRX - BioLineRx&#39;s lead oncology candidate BL-8040 shows encouraging action in preclinical study; shares ahead 5% https://seekingalpha.com/news/3324486-biolinerxs-lead-oncology-candidate-blminus-8040-shows-encouraging-action-in-preclinical-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3324486-biolinerxs-lead-oncology-candidate-blminus-8040-shows-encouraging-action-in-preclinical-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324484\" data-ts=\"1516718290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWW\" target=\"_blank\">GWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324484-ubs-negative-on-grainger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS negative on Grainger</a></h4><ul> <li>W.W. Grainger (NYSE:<a href='https://seekingalpha.com/symbol/GWW' title='W.W. Grainger, Inc.'>GWW</a>) opens <font color='red'>0.55% lower</font> after UBS starts off coverage on the industrial supply retailer with a Sell rating.</li> <li>The bold call comes a day ahead of Grainger's scheduled earnings report.</li> <li>Shares of Grainger are up 16% over the last 90 days to push the PE ratio above the historic norm.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324484\" data-linked=\"UBS negative on Grainger\" data-tweet=\"$GWW - UBS negative on Grainger https://seekingalpha.com/news/3324484-ubs-negative-on-grainger?source=tweet\" data-url=\"https://seekingalpha.com/news/3324484-ubs-negative-on-grainger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324482\" data-ts=\"1516718186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLNX\" target=\"_blank\">XLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324482-keybanc-raises-xilinx-price-target-to-15-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc raises its Xilinx price target to 15% upside</a></h4><ul><li>        KeyBanc <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Xilinx+%28XLNX%29+PT+Raised+to+%2487+at+KeyBanc/13710423.html\" target=\"_blank\">raises</a> its Xilinx (NASDAQ:<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a>) price target from $78 to $87 and maintains an Overweight rating.</li><li>               The new price target represents a 15% upside to yesterday&rsquo;s closing price.&nbsp;</li><li>               Xilinx shares are&nbsp;<font color='green'>up 0.7%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3324482\" data-linked=\"KeyBanc raises its Xilinx price target to 15% upside\" data-tweet=\"$XLNX - KeyBanc raises its Xilinx price target to 15% upside https://seekingalpha.com/news/3324482-keybanc-raises-xilinx-price-target-to-15-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3324482-keybanc-raises-xilinx-price-target-to-15-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324480\" data-ts=\"1516717676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324480-verizonplus-1_7-after-tax-reform-spurs-hefty-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon +1.7% after tax reform spurs hefty revenue beat</a></h4><ul>   <li>Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a>) is <font color='green'>up 1.7%</font> premarket after posting <a href=\"https://seekingalpha.com/news/3324385-verizon-misses-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a> where revenue solidly beat expectations and profits jumped, with a boost from late-breaking corporate tax reform.</li>    <li>EPS more than quadrupled in GAAP terms, while non-GAAP EPS was flat at $0.86. Adjusted EPS included a net pretax loss of about $2.6B along with a one-time after-tax boost to earnings estimated at $16.8B (about $4.10/share), among other adjustments.</li>    <li>The company posted 1.2M retail postpaid net subscriber additions in Q4, which includes 647,000 postpaid smartphone net adds (431,000 net phone additions). The total included 193,000 tablet net adds and 550,000 other connected devices, led by wearables.</li>    <li>Retail postpaid churn was at 1%, and retail postpaid phone churn was 0.77% (under 0.9% for the 11th straight quarter, Verizon notes).</li>    <li>Revenue breakout: Service revenues, $27.48B (up 3.3%); Wireless equipment revenues, $6.48B (up 13%).</li>    <li>For 2018, it's guiding to low-single-digit revenue growth and EPS growth on a GAAP basis and, excluding new revenue recognition impact, expects to hit Y/Y wireless service revenue growth by mid-2018. Capital spending will be $17B-$17.8B including a commercial 5G launch, and expected tax reform savings will give to $3.5B-$4B uplift to cash flow from operations, yielding a $0.55-$0.65 gain in 2018 EPS.</li>    <li><a href=\"https://seekingalpha.com/article/4139320-verizon-communications-2017-q4-results-earnings-call-slides\" target=\"_blank\">Earnings slides</a></li>    <li><a href=\"https://seekingalpha.com/pr/17053194-verizon-closes-2017-strong-wireless-customer-growth-retention-well-positioned-new-markets\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3324480\" data-linked=\"Verizon +1.7% after tax reform spurs hefty revenue beat\" data-tweet=\"$VZ - Verizon +1.7% after tax reform spurs hefty revenue beat https://seekingalpha.com/news/3324480-verizonplus-1_7-after-tax-reform-spurs-hefty-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3324480-verizonplus-1_7-after-tax-reform-spurs-hefty-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324478\" data-ts=\"1516717599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBLN\" target=\"_blank\">OBLN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324478-obalon-therapeutics-cancels-stock-offering-on-alleged-improper-q4-revenue-recognition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obalon Therapeutics cancels stock offering on alleged improper Q4 revenue recognition</a></h4><ul><li>Obalon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a>) has <a href=\"https://seekingalpha.com/pr/17053721-obalon-announces-termination-public-offering-common-stock\" target=\"_blank\">canceled </a>its public offering of ~5.5M shares of common stock at $5.50 per share after a whistleblower contacted auditor KPMG LLP claiming the company improperly recognized certain revenues in Q4 2017.</li><li>Obalon was notified of the issue only yesterday so it has not had time to complete its investigation into the matter. Management believes no material adjustments will be necessary, based on information it has at present.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3323814-obalon-prices-stock-offering-5_50-shares-6-percent-premarket\" target=\"_blank\">Obalon prices stock offering at $5.50; shares down 6% premarket</a> (Jan. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324478\" data-linked=\"Obalon Therapeutics cancels stock offering on alleged improper Q4 revenue recognition\" data-tweet=\"$OBLN - Obalon Therapeutics cancels stock offering on alleged improper Q4 revenue recognition https://seekingalpha.com/news/3324478-obalon-therapeutics-cancels-stock-offering-on-alleged-improper-q4-revenue-recognition?source=tweet\" data-url=\"https://seekingalpha.com/news/3324478-obalon-therapeutics-cancels-stock-offering-on-alleged-improper-q4-revenue-recognition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324477\" data-ts=\"1516717576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMB\" target=\"_blank\">KMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324477-on-kimberly-clarks-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Kimberly-Clark&#39;s Q4</a></h4><ul><li>Kimberly-Clark (NYSE:<a href='https://seekingalpha.com/symbol/KMB' title='Kimberly-Clark Corporation'>KMB</a>) reports organic sales fell 1% in <a href=\"https://seekingalpha.com/pr/17053226-kimberly-clark-announces-year-end-2017-results-2018-outlook-new-global-restructuring-multi\" target=\"_blank\">Q4</a>.</li><li>North American consumer products organic sales dropped 3%.</li><li>Developing and emerging markets organic sales rose 4% for the period.</li><li>Foreign currency exchange rates&nbsp;benefited&nbsp;sales by more than 1%.</li><li>Segment revenue: Personal care: $2.27B (+1%); Consumer Tissue: $1.5B (-1%); K-C Professional: $803M (+3%).</li><li>Gross margin rate squeezed 200 bps to 34.9%.</li><li>Segment operating profit:&nbsp;Personal care: $483M (-2%); Consumer Tissue: $258M (-13%); K-C Professional: $151M (+3%).</li><li>Operating margin rate down 80 bps to 17.7%.</li><li><b>FY2018 Guidance</b>: Net sales:&nbsp;+1% to +2%; Organic sales: ~+1%;&nbsp;Adjusted operating profit: +2% to +5%; Tax rate: 23% to 26%;&nbsp;Diluted EPS: $3.90 to $4.50; Adjusted EPS: $6.90 to $7.20; Capital expenditure: ~$1.1B.</li><li>KMB&nbsp;<font color='green'>+1.56%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3324477\" data-linked=\"More on Kimberly-Clark&#39;s Q4\" data-tweet=\"$KMB - More on Kimberly-Clark&#39;s Q4 https://seekingalpha.com/news/3324477-on-kimberly-clarks-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3324477-on-kimberly-clarks-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324476\" data-ts=\"1516717523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMBA\" target=\"_blank\">JMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324476-jamba-falls-after-large-block-of-shares-shopped\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jamba falls after large block of shares shopped</a></h4><ul> <li>Jamba (NASDAQ:<a href='https://seekingalpha.com/symbol/JMBA' title='Jamba, Inc.'>JMBA</a>) is <font color='red'>down 10.83%</font> in premarket trading on volume of over 18K shares.</li> <li>A block of 2.1M shares from an unknown seller is said to have priced at $8.25 per Bloomberg.</li><li>Jamba closed at $9.14 yesterday.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3324476\" data-linked=\"Jamba falls after large block of shares shopped\" data-tweet=\"$JMBA - Jamba falls after large block of shares shopped https://seekingalpha.com/news/3324476-jamba-falls-after-large-block-of-shares-shopped?source=tweet\" data-url=\"https://seekingalpha.com/news/3324476-jamba-falls-after-large-block-of-shares-shopped\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324475\" data-ts=\"1516717458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324475-premarket-gainers-of-9-05-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (1/23/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+39%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='green'>+21%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17053451-chinanet-online-holdings-announces-new-joint-venture-blockchain-technology-development\" target=\"_blank\">entering</a> into an agreement with Wuxi Jingtum Network Technology.</li>     <li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+14%</font>&nbsp;as <a href=\"https://seekingalpha.com/pr/17053399-aethlon-medical-announces-validation-completion-european-patent-protecting-methods\" target=\"_blank\">validation</a> has completed and the opposition period expired for European Patent Number 2591359.</li>     <li><a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+11%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3324243-netflix-eps-line-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+10%</font>&nbsp;on Trump administration <a href=\"https://seekingalpha.com/news/3324439-solar-stocks-mostly-higher-trump-tariffs-worse\" target=\"_blank\">tariffs</a>&nbsp;.</li>     <li><a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a> <font color='green'>+8%</font>&nbsp;on&nbsp;&nbsp;new U.S. <a href=\"https://seekingalpha.com/news/3324354-solar-names-respond-new-u-s-tariffs\" target=\"_blank\">tariffs</a>.</li>     <li><a href='https://seekingalpha.com/symbol/RMD' title='ResMed Inc.'>RMD</a> <font color='green'>+10%</font>&nbsp;on Q2 <a href=\"https://seekingalpha.com/news/3324247-resmed-beats-0_22-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+10%</font>&nbsp;on FY17 <a href=\"https://seekingalpha.com/pr/17053468-finjan-achieves-175-percent-increase-revenues-50-million-2017\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+6%</font>&nbsp;as U.S. Patent and Trademark Office has <a href=\"https://seekingalpha.com/pr/17053168-tonix-pharmaceuticals-receives-notice-allowance-new-u-s-patent-active-ingredient-tonmya\" target=\"_blank\">issued</a> a Notice of Allowance for&nbsp;U.S.&nbsp;Patent Application 12/948,828&nbsp;&ldquo;Methods and compositions for treating symptoms associated with posttraumatic stress disorder using cyclobenzaprine,&rdquo; covering the use of Tonmya*, or TNX-102 SL, for the treatment of posttraumatic stress disorder.</li>     <li><a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+8%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3324386-amarin-almost-reduce-shares-28-percent-premarket\" target=\"_blank\">announcement</a>&nbsp;that the large-scale REDUCE-IT cardiovascular outcomes study supporting Vascepa (icosapent ethyl) has reported more than 90% of the targeted 1,612 primary major adverse cardiovascular events.</li>     <li><a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='green'>+7%</font>&nbsp;on positive analyst <a href=\"https://seekingalpha.com/news/3324450-premarket-analyst-action-healthcare\" target=\"_blank\">action</a>.</li>     <li><a href='https://seekingalpha.com/symbol/LOGI' title='Logitech International S.A.'>LOGI</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color='green'>+6%</font>&nbsp;as immunotherapy candidate AGI-134 <a href=\"https://seekingalpha.com/news/3324413-biolinerxs-immunotherapy-candidate-agiminus-134-shows-positive-effect-preclinical-melanoma\" target=\"_blank\">shows</a> positive effect in preclinical melanoma studies.</li>     <li><a href='https://seekingalpha.com/symbol/ATI' title='Allegheny Technologies Incorporated'>ATI</a> <font color='green'>+5%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3324400-allegheny-technologies-beats-0_17-beats-revenue\" target=\"_blank\">earning</a>.</li>     <li><a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3324145-sorrento-builds-move-shares-ahead-19-percent\" target=\"_blank\">acquisition</a> of&nbsp; 1,801,801 shares of common stock and warrants to purchase up to 261,438 shares from a third party for a total of $11,531,526.40 ($6.40/share).</li>     <li><a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324475\" data-linked=\"Premarket Gainers as of 9:05 am (1/23/2018)\" data-tweet=\"$RGSE $CNET $AEMD - Premarket Gainers as of 9:05 am (1/23/2018) https://seekingalpha.com/news/3324475-premarket-gainers-of-9-05-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324475-premarket-gainers-of-9-05-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324474\" data-ts=\"1516717293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNJN\" target=\"_blank\">FNJN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324474-finjan-holdings-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finjan Holdings reports Q4 results</a></h4><ul><li>Finjan Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>): Q4 Revenue of $23.4M.</li><li>Shares <font color='green'>+6.36%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17053468-finjan-achieves-175-percent-increase-revenues-50-million-2017\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3324474\" data-linked=\"Finjan Holdings reports Q4 results\" data-tweet=\"$FNJN - Finjan Holdings reports Q4 results https://seekingalpha.com/news/3324474-finjan-holdings-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3324474-finjan-holdings-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324471\" data-ts=\"1516717003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNJN\" target=\"_blank\">FNJN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324471-finjanplus-6_4-on-q4-fy17-revenue-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finjan +6.4% on Q4, FY17 revenue beats</a></h4><ul><li>        Finjan (NASDAQ:<a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a>) <a href=\"https://seekingalpha.com/pr/17053468-finjan-achieves-175-percent-increase-revenues-50-million-2017\" target=\"_blank\">reports FY17 results</a> with over $50M in revenue (+175% Y/Y, consensus: $45.56M), $41M in cash, and $15M in income from operations.</li><li>               Q4 revenue increased 180% on the year to $23.4M (consensus: $18.5M).&nbsp;</li><li>               Notable events: Closed patent license agreements with FireEye and Sophos, ended a patent dispute with Avast, and signed new licenses with Veracode and Avira. &nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17053468-finjan-achieves-175-percent-increase-revenues-50-million-2017\" target=\"_blank\">Press release</a>&nbsp;</li><li>                  Earnings call at 4:30 PM Eastern Time. Find the webcast <a href=\"https://ir.finjan.com/ir-calendar\" target=\"_blank\">here</a>.    </li><li>                  Finjan shares are&nbsp;<font color='green'>up 6.4%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3320612-finjan-plus-13_4-percent-fireeye-agreement\" target=\"_blank\">Finjan +13.4% after FireEye agreement</a> (Jan. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3324471\" data-linked=\"Finjan +6.4% on Q4, FY17 revenue beats\" data-tweet=\"$FNJN - Finjan +6.4% on Q4, FY17 revenue beats https://seekingalpha.com/news/3324471-finjanplus-6_4-on-q4-fy17-revenue-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3324471-finjanplus-6_4-on-q4-fy17-revenue-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324466\" data-ts=\"1516716778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324466-snapchat-to-allow-stories-on-twitter-facebook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snapchat to allow Stories on Twitter, Facebook</a></h4><ul>   <li>Snapchat (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) will pursue growth by letting its users <a href=\"https://www.cnbc.com/2018/01/23/snapchat-stories-will-soon-be-shareable-on-twitter-and-facebook.html\" target=\"_blank\">share Stories to other linked social media</a>, including Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) and Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>).</li>    <li>That's a departure from past approaches where Snap worked to distance the key product from rival offerings.</li>    <li>Unlike Snap's signature disappearing messages sent to a single user, Stories were set to live on Snap's app and be replayable multiple times for 24 hours.</li>    <li>The update, part of a heavy redesign that Snap sought to undertake, means that stories can even be mailed or texted to others who don't have the app, and is available to those with the redesigned app starting Wednesday and rolling out over the next few weeks.</li>    <li>Premarket: <a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='red'>-0.6%</font>; <a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='red'>-2.8%</font>; <a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='green'>+0.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324466\" data-linked=\"Snapchat to allow Stories on Twitter, Facebook\" data-tweet=\"$SNAP $SNAP $TWTR - Snapchat to allow Stories on Twitter, Facebook https://seekingalpha.com/news/3324466-snapchat-to-allow-stories-on-twitter-facebook?source=tweet\" data-url=\"https://seekingalpha.com/news/3324466-snapchat-to-allow-stories-on-twitter-facebook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324463\" data-ts=\"1516716568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324463-premarket-losers-of-9-05-1-23-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (1/23/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='red'>-18%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17053047-brucejack-mine-production-update-2018-guidance\" target=\"_blank\">providing</a> 2018 guidance.</li><li><a href='https://seekingalpha.com/symbol/JMBA' title='Jamba, Inc.'>JMBA</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3324463\" data-linked=\"Premarket Losers as of 9:05 am (1/23/2018)\" data-tweet=\"$PVG $JMBA $LTBR - Premarket Losers as of 9:05 am (1/23/2018) https://seekingalpha.com/news/3324463-premarket-losers-of-9-05-1-23-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3324463-premarket-losers-of-9-05-1-23-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3324461\" data-ts=\"1516716464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3324461-analysts-reset-on-netflix-after-subscriber-growth-dazzles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts reset on Netflix after subscriber growth dazzles</a></h4><ul> <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color='green'>up 11%</font> in premarket action after the company's strong subscriber growth sends analysts scrambling to crunch numbers again. Piper Jaffray <a href=\"https://www.streetinsider.com/Analyst+EPS+Change/Netflix%2C+Inc.+%28NFLX%29%3A+Reaching+Escape+Velocity%2C+PT+To+%24281+-+Piper+Jaffray/13711075.html\" target=\"_blank\">summed up</a> the bull camp on the streamer when it maintained that Netflix has reached \"escape velocity\" in its path to stay ahead of content spending.</li> <li>On the Netflix conference call, execs disclosed a $39M write-down of future projects during the quarter. That mark appears to be related to the House of Cards issue after a large number of sexual harassment allegations against Kevin Spacey emerged.</li> <li>PT boosts on Netflix: Wells Fargo to $285, JPMorgan to $285, Goldman Sachs to $315, Buckingham Research to $257, Stifel Nicolaus to $283, Pivotal Research Group to $300.</li> <li><a href=\"https://seekingalpha.com/article/4139252-netflixs-nflx-ceo-reed-hastings-q4-2017-results-earnings-call-transcript\" target=\"_blank\">Netflix earnings call transcript</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3324256-netflix-smashes-subscriber-estimates\" target=\"_blank\">Netflix smashes subscriber estimates</a> (Jan. 22)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3324461\" data-linked=\"Analysts reset on Netflix after subscriber growth dazzles\" data-tweet=\"$NFLX - Analysts reset on Netflix after subscriber growth dazzles https://seekingalpha.com/news/3324461-analysts-reset-on-netflix-after-subscriber-growth-dazzles?source=tweet\" data-url=\"https://seekingalpha.com/news/3324461-analysts-reset-on-netflix-after-subscriber-growth-dazzles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}